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Abstract
In December 2019, China reported the first cases of the coronavirus disease 2019 
(COVID-19). This disease, caused by the severe acute respiratory syndrome–related 
coronavirus 2 (SARS-CoV-2), has developed into a pandemic. To date, it has resulted 
in ~9 million confirmed cases and caused almost 500 000 related deaths worldwide. 
Unequivocally, the COVID-19 pandemic is the gravest health and socioeconomic 
crisis of our time. In this context, numerous questions have emerged in demand 
of basic scientific information and evidence-based medical advice on SARS-CoV-2 
and COVID-19. Although the majority of the patients show a very mild, self-limiting 
viral respiratory disease, many clinical manifestations in severe patients are unique 
to COVID-19, such as severe lymphopenia and eosinopenia, extensive pneumonia, 
a “cytokine storm” leading to acute respiratory distress syndrome, endothelitis, 
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1  | INTRODUC TION
The first cases of the coronavirus disease 2019 (COVID-19), caused 
by the novel severe acute respiratory syndrome–related coronavi-
rus 2 (SARS-CoV-2), were reported in China in December 20191 and 
rapidly led to pandemic. Currently, ~9 million confirmed cases of 
COVID-19 and near 500 000 COVID-19–related deaths have been 
reported globally.2
These numbers, which are still rising, likely underestimate the 
cumulative incidence of COVID-19 due to several factors; these in-
clude limitations of current diagnostic tests, the extent of population 
testing and reporting, and the type and timing of community mitiga-
tion strategies adopted by each country, among others.3 COVID-19 
shows a complex clinical profile with many different presentations. 
Like in many other viral infections, subclinical, mild, moderate, or se-
vere cases (10%-20% of patients require hospitalization and 2%-4% 
intensive care unit, ICU) presenting with or without pneumonia are 
observed. Asymptomatic cases are common, but, to date, there is a 
lack of epidemiological surveys that provide a clear percentage of 
asymptomatic cases.4,5
The COVID-19 pandemic is the world's gravest public health cri-
sis of the 21st century, and there is an urgent need for reliable and 
updated scientific and clinical information. COVID-19 is a zoonosis 
that has now spread worldwide, and it will be practically impossible 
to eradicate the SARS-CoV-2 without vaccination. The main ques-
tion will be to learn how to cope with this virus, as COVID-19 is 
becoming an important reason for morbidity and mortality in many 
countries. The aim of this paper was to provide short answers to 
pressing questions on virology, immunology, diagnostics, epide-
miology, and treatment, as well as optimal management of allergic 
diseases during the COVID-19 pandemic. These 150 answers are 
provided by a group of expert scientists and physicians, mainly from 
the European Academy of Allergy and Clinical Immunology (EAACI), 
and are grouped in 9 sections. All the information will be updated in 
light of new upcoming evidence.
2  | SEC TION 1:  SARS- COV-2 VIROLOGY
2.1 | What is known about the origin of SARS-
CoV-2?
The coronavirus family has caused zoonotic diseases such the Middle 
East respiratory syndrome (MERS). While a direct ancestor of SARS-
CoV-2 is unknown, it is closely related to β-coronaviruses in bats 
and pangolins, which are likely its original reservoir. SARS-CoV-2 
could have risen by selection in the animal host followed by zoonotic 
transfer and acquisition of further mutations in humans. It is possi-
ble that, during undetected human-to-human transmission, the virus 
mutated, optimizing the binding of its spike protein to human angi-
otensin-converting enzyme 2 (ACE2) (Figure 1). Importantly, avail-
able SARS-CoV-2 genetic data do not evince an intentional human 
manipulation of the virus.6
2.2 | What are the strains of SARS-CoV-2?
Three SARS-CoV-2 variants have been identified (A, B, and C), which 
differ in their amino acid sequences. The ancestral type A and the 
mutated type C are found in significant proportions outside East 
Asia, mainly in Europe and in the USA. Type B, which has mutated 
and spread, is the most common strain in East Asia.7 Continuous 
genome sequencing of virus mutations is needed to monitor the 
pandemic.
thromboembolic complications, and multiorgan failure. The epidemiologic features of 
COVID-19 are distinctive and have changed throughout the pandemic. Vaccine and 
drug development studies and clinical trials are rapidly growing at an unprecedented 
speed. However, basic and clinical research on COVID-19–related topics should be 
based on more coordinated high-quality studies. This paper answers pressing ques-
tions, formulated by young clinicians and scientists, on SARS-CoV-2, COVID-19, and 
allergy, focusing on the following topics: virology, immunology, diagnosis, manage-
ment of patients with allergic disease and asthma, treatment, clinical trials, drug 
discovery, vaccine development, and epidemiology. A total of 150 questions were 
answered by experts in the field providing a comprehensive and practical overview 
of COVID-19 and allergic disease.
K E Y W O R D S
allergy, coronavirus disease 2019, COVID-19, SARS-CoV-2, severe acute respiratory 
syndrome–related coronavirus 2
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2.3 | What are the main receptors used by SARS-
CoV-2 for cell entry?
SARS-CoV-2 binds to ACE2 via its spike protein to enter human 
cells.8 Cell entry is facilitated by the host transmembrane protease, 
serine 2 (TMPRSS2) that cleaves the spike protein into S1 and S2 
fragments, thus enabling cellular membrane fusion (Figure 1).9 ACE2 
is highly expressed in the lungs, small intestine, kidney, and heart, 
but not in innate and adaptive immune cells.10-13 SARS-CoV-2 also 
binds to CD147 (known as basigin or extracellular matrix metallo-
proteinase inducer), which is expressed in human airway and kid-
ney epithelium, as well as in innate cells and lymphocytes,10 and to 
TMPRSS4, which is highly expressed in intestinal epithelial cells.14 
In addition, antibody-dependent enhancement of SARS-CoV-2 cell 
entry may also contribute to infection as reported for SARS-CoV.15
2.4 | Are there other molecules potentially used by 
SARS-CoV-2 for cell entry?
SARS-CoV-2 may use receptors that have been reported for other 
coronaviruses, such as CD26, aminopeptidase N, and glutamyl amin-
opeptidase, for cell invasion.13,16,17 Among these, CD26 (encoded by 
DPP4) has emerged as a putative receptor for SARS-CoV-2 because 
F I G U R E  1   SARS-CoV-2 attachment, internalization, and replication cycle in epithelial cells and the main effect of antiviral agents. 
Attachment of SARS-CoV-2 spike protein (S) to angiotensin-converting enzyme 2 (ACE2) mediates endocytosis of the virus into the host cell. 
The cell entry of the virus depends on both the binding of viral S proteins to cellular receptors and priming S protein by the transmembrane 
protease,serine 2 (TMPRSS2). Cepharanthine/ human recombinant ACE2 and camostat mesylate are the viral entry inhibitors, which 
prevent the binding of S protein to ACE2 and priming, respectively. In the uncoating stage, virions are internalized by receptor-mediated 
endocytosis that the low pH in the endosome triggers the fusion of viral and endosomal membranes and the single strand RNA is released 
into the cytoplasm. Arbidol, chloroquine, hydroxychloroquine, and mefloquine block this uncoating stage. Transcription of the viral genome 
and proteolytic cleavage of the replicase polyprotein and resulting translating proteins are processed into the viral RNA-dependent RNA 
polymerase (RdRp). Lopinavir, ritonavir, remdesivir, and favipiravir prevent proteolysis and activity of RdRp. Nonstructural and structural 
proteins, including nucleocapsid proteins are expressed as subgenomic RNAs. Selamectin and resveratrol may inhibit viral helicase activity, 
viral mRNA synthesis, and the expression of nucleocapsid proteins. Assembly and budding of viral proteins and nucleocapsid occur at 
membranes of the endoplasmic reticulum (ER), the ER-Golgi intermediate compartment (ERGIC), and/or the Golgi complex. New SARS-
CoV-2 virions are released by exocytosis
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structural analyses predict that the spike protein of SARS-CoV-2 
binds to CD26.18 This receptor has been shown to be expressed in 
the human epithelium and immune cells.10
2.5 | Are there ACE2 polymorphisms that affect 
COVID-19 severity?
There is limited evidence about COVID-19–associated polymor-
phisms. ACE might be one of the candidate genes that influences 
pneumonia progression in SARS. It is conceivable that the D allele in-
fluences the renin-angiotensin system via elevation of serum or local 
ACE levels, which may damage the endothelium or epithelium of the 
lungs.19 The variance in COVID-19 prevalence and mortality cannot 
be explained by an ACE insertion or deletion polymorphism alone, or 
one polymorphism of any single gene. However, polymorphisms in 
genes of Toll-like receptors, inflammasome, intracellular molecular 
sensors, interferons (IFNs),20 and interleukins (ILs) may contribute.
2.6 | What are the main SARS-CoV-2 molecules 
eliciting the immune response?
Structural proteins of SARS-CoV-2 virions, such as the spike glyco-
protein, envelope, membrane, and nucleocapsid, are the main immu-
nogenic molecules (Figure 1).21,22 SARS-CoV-2 adaptive responses 
develop mainly to the spike protein, and immunodominant T- and 
B-cell epitopes have been reported.23 Intracellularly, the viral RNA 
replicase complex, and nonstructural and translated proteins, acti-
vates innate immune pathways. This leads to an IFN type I response, 
NF-kB activation in epithelial cells, and activation of NLRP3 and 
other inflammasomes, in macrophages and dendritic cells.22
2.7 | What are the main structural differences of 
SARS-CoV-1 and SARS-CoV-2?
The spike protein of SARS-CoV-2 has a receptor-binding domain 
that binds ACE2 with higher affinity than SARS-CoV.8 In addition, 
the SARS-CoV-2 spike protein harbors a polybasic furin cleavage site 
(PRRAR) with an insertion of 4 amino acid residues, which is distinct 
from that found in SARS-CoV and other SARS-like viruses. This al-
lows effective cleavage by furin and other proteases and determines 
viral infectivity and host range.6
2.8 | Are there any similarities in the immune 
response to human immunodeficiency virus (HIV) and 
SARS-CoV-2?
The severe lymphopenia observed in COVID-1924 is similar to that 
reported in HIV infection and acquired immune deficiency syn-
drome. The latter is characterized by CD4+ T-cell lymphopenia, 
whereas COVID-19 causes general lymphopenia. However, severe 
lymphopenia development in COVID-19 happens in weeks, whereas 
HIV-induced lymphopenia takes years.25 HIV and SARS-CoV-2 are 
both RNA viruses and share some similarities in their replication 
pathways; hence, certain RNA replication drugs may work in both 
diseases (Figure 1).26
2.9 | Is the generation of mutated and more 
pathogenic strains of SARS-CoV-2 expected?
There are 2 strains of SARS-CoV-2 that are clinically relevant. Genome 
analysis of SARS-CoV-2 from human samples shows high rates of mu-
tation and deletion in several viral genes, including the spike glyco-
protein gene.27 COVID-19 treatments, including future vaccination 
against SARS-CoV-2, may drive the genetic evolution of the virus af-
fecting virulence and pathogenicity. For example, a report on a 382-nt 
deletion in ORF8 (Figure 1) of SARS-CoV2 isolated from patients in 
Singapore implied that mutations may arise as a result of human adap-
tation and could be associated with attenuation.28 Nevertheless, the 
emergence of a SARS-CoV-3 is possible as long as there is close con-
tact between humans and living animals that harbor coronaviruses.
2.10 | For how long is SARS-CoV-2 detected 
in oral and respiratory secretions from COVID-19 
patients?
Data from 96 COVID-19 patients in China show SARS-CoV-2 detec-
tion in respiratory samples for a median of 18 days (13-29 days). In 
this study, sputum and saliva were not analyzed separately. Viral 
shedding was significantly longer in patients with severe disease, 
with a median of 21 days (14-30 days), compared with mild disease, 
with a median of 14 days (10-21 days). Furthermore, glucocorticoid 
treatment longer than 10 days significantly extended the duration 
of SARS-CoV-2 shedding.29 Viral load differed significantly by sam-
ple type, with respiratory samples showing the highest, followed by 
stool samples, and serum samples showing the lowest (Figure 2).29 
Another study of 78 patients with COVID-19 (33 asymptomatic vs 
42 symptomatic) has estimated that the duration of viral shedding 
from nasopharynx swabs was 8 days (3-12 days) for asymptomatic 
vs 19 days (16-24 days) for symptomatic patients.30 The viral load 
ranged from 1.34 × 1011 copies per mL to 7.52 × 105 in sputum of 
patients who died and survived, respectively.31
2.11 | What is the relevance of the fecal-oral route 
in SARS-CoV-2 transmission?
TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of ACE-
expressing human enterocytes14 causing diarrhea in adults and chil-
dren.32,33 SARS-CoV-2 has been detected in stool samples by reverse 
transcription-polymerase chain reaction (RT-PCR) (Figure 2). The 
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median duration of the virus in stool samples (22 days, interquartile 
range 17-31 days) was significantly longer than in respiratory sam-
ples (18 days, 13-29 days).29 However, SARS-CoV-2 released into the 
intestinal lumen was inactivated by simulated human colonic fluid, 
and infectious virus was not recovered from the stool specimens of 
patients with COVID-19. Therefore, the intestine is a potential site of 
SARS-CoV-2 replication, which may contribute to local and systemic 
illness and overall disease progression but unlikely to contribute to the 
spreading of COVID-19.14
3  | SEC TION 2:  IMMUNOLOGY OF 
COVID -19
3.1 | B-cell and antibody responses
3.1.1 | What is the time of seroconversion and 
duration of IgM and IgG responses against SARS-
CoV-2?
From previous SARS studies, it is known that the median sero-
conversion time for detectable IgG was 17 days after infection.34 
Detectable levels of SARS-specific IgG and neutralizing antibodies 
persisted for up to 720 days. This suggests that there is antibody-
mediated protection from SARS-CoV recurrent infection for up 
to 2 years.35 There are inconsistent reports on the humoral re-
sponse to SARS-CoV-2. One study with 285 COVID-19 patients 
reported that SARS-CoV-2 virus-specific IgG and IgM peaked 
17-19 days and 20-22 days after symptom onset, respectively.36 
On the other hand, another study of 26 hospitalized COVID-19 
patients showed that seroconversion could take up to 50 days.37 
These discrepancies may be related to the time of SARS-CoV-2 
diagnosis or the clinical characteristics of each cohort and warrant 
additional studies.
3.1.2 | What is the role of IgA in SARS-CoV-2 
infection?
Systemic IgA responses may play a relevant role in the pathogen-
esis of COVID-19.38 Mucosal IgA likely exerts a protective role by 
preventing SARS-CoV-2 adherence to epithelial cells. Circulatory 
IgA may also contribute to SARS-CoV-2 neutralization. In addition, 
IgA has the ability either to promote inflammation, through the 
formation of immune complexes, or to dampen it via Fc-mediated 
inhibitory ITAM signaling.39,40 A seroconversion study in COVID-
19 patients has found an association between disease severity and 
SARS-CoV-2–specific IgA levels. These were significantly higher 
than SARS-CoV-2–specific IgM and IgG levels in critically ill COVID-
19 patients.38 Whether this association, previously unseen in SARS-
CoV infection,41 is due to a protective or detrimental role of IgA in 
COVID-19 remains to be elucidated.
3.1.3 | Are there differences in the SARS-CoV-2 
antibody response between asymptomatic and 
symptomatic patients?
Preliminary findings indicate that asymptomatic and mild cases of 
COVID-19 can generate detectable levels of SARS-CoV-2–specific 
antibodies in serum. However, seroconversion is observed less fre-
quently in asymptomatic compared with mild or severe cases, and 
F I G U R E  2   Diagnosis of SARS-CoV-2 infection through different diagnostic tests over time according to incubation period, disease onset, 
clinical disease, and convalescence
     |  2509RIGGIONI et al.
many asymptomatic cases yield undetectable SARS-CoV-2–specific 
antibody responses.36,42-44 So far, no robust data are available on the 
qualitative differences in humoral responses between asymptomatic 
and symptomatic COVID-19 patients.
3.1.4 | Children tend to have mild forms of 
COVID-19, what is known about the specificity and 
affinity of their SARS-CoV-2 antibody response?
It is not clear which molecular mechanisms underlie the milder symp-
toms of COVID-19 in children as compared to adults. Children may 
mount a SARS-CoV-2 antibody response characterized by more ef-
ficient production of the so-called natural antibodies, which arise 
from activated IgM + memory B cells.45 These cells, which are more 
prevalent in children than in adults, presumably produce broadly 
neutralizing antibodies early during the infection.
3.1.5 | The generation of B-cell memory 
contributes to long-term immunity. 
Has the extent and quality of SARS-CoV-2 memory 
responses been evaluated?
B-cell receptor sequencing has been conducted in the blood of 
COVID-19 patients. Naive B cells exhibited little clonal expansion, 
whereas CD27+ CD38+ memory B cells showed the highest ex-
pansion levels among diverse B-cell subsets. COVID-19 patients 
significantly expanded specific B-cell receptor clones compared 
with those in the healthy controls. These findings suggest that B 
cells experience unique clonal variable, diversity, and joining gene 
segment rearrangements upon SARS-CoV-2 infection.46 The life 
span and functionality of these B cells remain to be elucidated.
3.1.6 | Is the immunity acquired during the first 
COVID-19 wave enough for “herd immunity”?
The term “herd immunity” refers to the generation of population 
immunity that protects a region, or country, from infection.47 The 
number of confirmed COVID-19 cases has reached approximately 
9 million.2 The world population is estimated to be 7.8 billion. To 
ascertain the extent of herd immunity, it is pivotal to define the 
prevalence of SARS-CoV-2–exposed humans. It is thought that 
67% is the minimum percentage of symptomatic or asymptomatic 
COVID-19 population required for herd immunity.47 That is to say 
that worldwide herd immunity may occur when ~5 billion humans 
have a protective immune response against SARS-CoV-2. To date, 
there are no reliable data, particularly on the number of asympto-
matic individuals that show seroconversion, to determine the degree 
of herd immunity.48
3.1.7 | Given the role of IL-4 in immunoglobulin 
class switching and germinal center reactions, could 
IL-4 axis-targeting treatments cause defective B-cell 
responses against SARS-CoV-2?
IL-4 is pleiotropic and could theoretically cause negative effects on 
immune responses. However, based on phase II and III studies with 
dupilumab (an IL-4Rα–specific monoclonal antibody that blocks IL-4 
and IL-13 signaling) in the context of atopic dermatitis, chronic rhi-
nosinusitis with nasal polyps, and asthma, no increased risk of in-
fections to viral or bacterial pathogens have been documented.49 
Furthermore, dupilumab had no impact on responses to nonlive 
vaccines.50
3.2 | Type 2 responses and eosinophils
3.2.1 | Does type 2 airway inflammation protect 
against COVID-19?
Allergic airway disease patients appear to be underrepresented 
among COVID-19 patients.51-53 This could be partly attributed to 
the low ACE2 expression detected in allergic patients, with or with-
out concomitant asthma.54 Furthermore, allergen challenge, which 
induces T-helper (Th) 2 inflammation,55 has been shown to reduce 
ACE2 expression in a murine model of asthma, and ACE2 expres-
sion was inversely associated with type 2 biomarkers (IL-13, IgE, 
exhaled nitric oxide fraction).56 These results are in line with pre-
vious work showing that decreased ACE expression in the airway 
epithelium of asthmatic subjects was associated with eosinophilic 
inflammation.57 On the other hand, the analysis of nasal airway 
transcriptome data from 695 children identified that TMPRSS2 
is highly upregulated by type 2 inflammation through the action 
of IL-13. Therefore, the reduced ACE2 expression seen in asth-
matic patients may be compensated by an increase in TMPRSS2 
production.58
3.2.2 | Some COVID-19 patients present with 
eosinophilic inflammation. Is it a Th2-driven response 
against the virus or an innate immune response?
Eosinopenia has been reported in ~50%-70% of severe COVID-19 
patients. A minority of COVID-19 patients present with eosinophilic 
inflammation.24,59 The Th1/Th2 cytokine balance may play a role, 
particularly as it pertains to IL-5, which promotes eosinophilopoie-
sis and eosinophil survival and activation. Eosinophilic inflammation 
suggests the dominance of type 2 inflammation, which may play 
a protective role against SARS-CoV-2. On the other hand, it may 
be the result of a hypersensitivity reaction to drugs used to treat 
COVID-19.60-62
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3.2.3 | Do eosinophils exert antiviral activity in 
COVID-19 patients?
Anti-IL-5 treatment, which induces eosinophil deficiency, results 
in a higher viral load in influenza and rhinovirus infection. This 
might be due to the ability of eosinophils to bind and inactivate 
the influenza A virus and respiratory syncytial virus (RSV).63 A 
similar role seems possible in SARS-CoV-2 infection, where type 
2 asthma patients potentially benefit from antiviral eosinophil 
responses. On the other hand, COVID-19 postmortems did not 
show lung eosinophilia,61 which argues against its local protec-
tive role in SARS-CoV-2 infection, although it is important to 
control for glucocorticoid-driven eosinophil reduction in these 
studies.60
3.2.4 | What is the mechanism underlying 
eosinopenia in COVID-19 patients?
Eosinopenia is commonly reported in severe COVID-19.64,65 The 
underlying mechanisms are largely unknown and most likely 
multifactorial. A number of possible explanations have been 
proposed: decreased eosinophilopoiesis; defective eosinophil 
egression from the bone marrow; and eosinophil apoptosis in-
duced by type 1 IFN released during the acute infection.60 Also, 
increased eosinophil migration and retention within inflamed tis-
sues has been described,66 but disputed for the aforementioned 
reasons.61
3.2.5 | Do eosinophil-targeting biologics affect 
COVID-19 patients?
There is no evidence for an enhanced susceptibility of patients on 
anti-IL-5/IL-5R treatment to develop viral infections. Observational 
studies in COVID-19 patients reported elevated eosinophil counts 
with a favorable outcome, whereas eosinopenia was observed 
in more severe cases.24,67 Neither was there proof of causation 
nor evidence for enhanced tissue presence in lungs of COVID-19 
patients.68
3.2.6 | Do IL-5-targeting therapies for 
asthma have a protective effect in COVID-19 
patients with severe asthma who are already 
receiving these therapies?
There is neither evidence for a protective effect of these biologicals 
nor a negative effect regarding SARS-CoV-2 infection. Importantly, 
maintaining proper asthma control is imperative and so is to follow 
up on severe asthmatics during the COVID-19 pandemic, for exam-
ple, via telemedicine.49
3.2.7 | Will helminth coinfection modulate 
COVID-19 severity in endemic regions?
More than 1 billion people worldwide are infected with helminths, 
with those living in resource-poor tropical areas being disproportion-
ately affected. Helminth coinfection has been shown to influence 
the severity of viral infection in mice, for example, murid herpesvirus 
4 respiratory infection, prior infection with Schistosoma mansoni, and 
reduced disease severity.69 However, immune responses to pulmo-
nary coronaviruses and murid herpesvirus 4 are different, and there-
fore, the impact of helminth coinfection is yet to be determined. This 
is particularly important as the pandemic is now spreading through 
the helminth-endemic regions of the word.70
3.3 | T cells and lymphopenia
3.3.1 | Is T-cell function impaired in SARS-CoV-2 
infection?
SARS-CoV-2 infects human T cells via CD147 binding.71 T cells are 
severely affected by SARS-CoV-2, which reduces T-cell counts nearly 
2 times below the reference limit. This effect is more pronounced in 
critically ill COVID-19 patients.59,72,73 In addition to the reduction in 
T-cell numbers, a recent study found that CD4+ and CD8+ T cells 
and natural killer cells displayed reduced antiviral cytokine produc-
tion in COVID-19 patients. A reduced cytotoxic potential was identi-
fied in COVID-19 patients, particularly in those that required ICU, 
and was associated with high IL-6 serum levels.74
3.3.2 | What is the specificity of the T-cell response 
generated in COVID-19 patients?
Circulating SARS-CoV-2-specific CD8+ and CD4+ T cells have been re-
ported in ∼70% and 100% of COVID-19 convalescent patients, respec-
tively.75 CD4+ T-cell responses to the spike protein were robust and 
correlated with SARS-CoV-2–specific IgG and IgA titers. The M spike and 
N proteins each accounted for 11%-27% of the total CD4+ response, 
with additional responses commonly targeting nsp3, nsp4, ORF3a, 
and ORF8, among others. For CD8+ T cells, spike and M proteins were 
recognized, with at least 8 SARS-CoV-2 ORFs targeted. Interestingly, 
SARS-CoV-2-reactive CD4+ T cells were detected in ∼40%-60% of 
unexposed individuals, which indicate cross-reactive T-cell recognition 
between circulating “common cold” coronaviruses and SARS-CoV-2.75
3.3.3 | Is a long-term T-cell memory established 
during SARS-CoV-2 infection?
Three SARS-recovered individuals, 9 and 11 years postinfection, 
were analyzed for T-cell responses against 550 SARS-CoV peptides 
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that may share homology with MERS-CoV. SARS-specific memory T 
cells persisted at 9 and 11 years post-SARS infection in the absence 
of antigen exposure.76 Based on these data, it is likely that specific 
SARS-CoV-2 epitopes elicit a persistent T-cell response, which may 
also confer protection against other “common cold” coronaviruses.75 
However, long-term studies on the natural history of SARS-CoV-2 
infection are pending.
3.3.4 | What are the hypothetical mechanisms of 
lymphopenia?
Different mechanisms have been proposed for lymphopenia: (a) 
T-cell exhaustion. The expression of programmed cell death-1 
marker (also known as PD-1), which is associated with T-cell exhaus-
tion, was higher in T cells from COVID-19 patients than in healthy 
controls; the expression of PD-1 and Tim-3 (another exhaustion 
marker) increased as COVID-19 progressed77; (b) activation of P53 
signaling in lymphocytes, which suggests a role of apoptosis in 
lymphopenia; (c) lymphocyte pyroptosis, which induces lymphope-
nia and may be proinflammatory78; (d) T-cell infection with SARS-
CoV-2, which may also cause a cytopathic effect on infected T cells; 
and (e) other mechanisms of lymphopenia that remain to be stud-
ied are bone marrow suppression during cytokine storm syndrome 
(CSS; see below) and sequestration in the lungs during extensive 
bilateral pneumonia.59
3.3.5 | Can lymphopenia be an early predictor of 
COVID-19 severity?
Lymphopenia can be used as an early predictor of severity and clini-
cal outcome. A significant reduction in lymphocyte counts was com-
mon in severe and critically ill COVID-19 patients. A continuing or 
gradual decrease in lymphocyte counts was indicative of poor prog-
nosis and usually required ICU admission (Table 1).59 In agreement 
with this, a number of studies have identified lymphopenia as an in-
dependent risk factor for mortality in COVID-19.24,79
3.3.6 | Which cells are particularly decreased in 
lymphopenia?
In COVID-19 patients, decreases were observed in total lympho-
cytes, CD4+ and CD8+ T cells, B cells, and natural killer cells. T-cell 
and natural killer cell counts were below normal levels, while B-cell 
counts were at the low end of the normal range. A reduction in 
specific subsets of lymphocytes, such as CD16+ CD56+ natural 
killer cells and regulatory T cells, was reported in severe COVID-19 
patients.59
3.4 | Immunopathology, immunosuppression, and 
immune regulation
3.4.1 | What is meant by CSS?
CSS is associated with a wide variety of diseases, both infec-
tious and noninfectious. It is a complex cascade of multicellular 
activation events that leads to an excessive or uncontrolled re-
lease of proinflammatory cytokines. CSS-associated inflamma-
tion begins at a local site and spreads throughout the body via 
the systemic circulation and can cause multiorgan failure and 
hyperferritinemia.59,80
3.4.2 | Which cells are critically contributing to CSS 
in severe COVID-19?
CSS encompasses the activation of large numbers of blood cells, 
including B cells, natural killer cells, macrophages, dendritic cells, 
neutrophils, monocytes, resident tissue cells, and epithelial and 
endothelial cells. Their activation causes a massive release of pro-
inflammatory cytokines, which drives pathology.81 The cells in-
volved in CSS during COVID-19 have not been fully determined 
yet. In SARS-CoV and MERS-CoV infection, airway epithelial cells, 
dendritic cells, and macrophages were the most important cell 
types releasing a large amount of proinflammatory cytokines.59,82
3.4.3 | Which cytokines are most elevated during 
CSS?
Multiple proinflammatory cytokines and inflammasome activa-
tion may contribute to CSS pathogenesis.59 Elevated serum ferri-
tin, IL-6, IL-1β, IFN-γ, CXCL10 (known as IP-10), and CCL2 (known 
as MCP-1) levels have been observed in the pathogenesis of se-
vere COVID-19.60,83 A recent study compared 48 cytokines in 53 
COVID-19 patients and 8 healthy individuals and found that 14 
of them were increased in COVID-19: IFN-γ, IL-1Rα, IL-2Rα, IL-6, 
Blood lymphocyte (%)
1st time point (10-12 d after 
symptom onset)
2nd Time point (17-19 d 
after symptom onset)
>20% Mild/ moderate disease Recovering group
5%-20% Severe disease At-risk group
<5% Severe disease Critically-ill group
TA B L E  1   Lymphopenia is associated 
with disease severity in COVID-19 
patients. Adapted from Azkur et al59
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IL-10, IL-18, hepatocyte growth factor, monocyte chemotactic 
protein-3, monokine-induced γ-IFN, macrophage colony-stimu-
lating factor, granulocyte colony-stimulating factor, macrophage 
inflammatory protein 1α, cutaneous T-cell–attracting chemokine, 
and IP-10. A consistently high level of IP-10, monocyte chemot-
actic protein-3, and IL-1Rα was associated with deterioration and 
fatal outcome.84
3.4.4 | Which other diseases can also develop CSS?
CSS can also develop in other infectious diseases such as bacterial 
sepsis, leptospirosis, Ebola and other hemorrhagic fevers, influ-
enza, other pathogenic coronavirus infections including SARS-CoV 
and MERS-CoV, severe RSV infection, and noninfectious diseases 
such as blunt trauma, and as a side effect of immune-stimulatory 
drugs.59,80
3.4.5 | Does systemic immunosuppression 
influence the course of COVID-19?
Immunosuppression is a double-edged sword in viral infections.85 
Patients receiving systemic immune suppression (eg, chemother-
apy) at the time of infection tend to develop a severe form of the 
disease. There are conflicting results regarding systemic corticos-
teroid treatment, but their usage is not generally recommended in 
viral infections.59,86,87 However, CSS treatment requires systemic 
immune suppression. Therefore, immune suppression may facili-
tate viral infection, but, at advanced stages of infection, it may 
be beneficial to counteract immunopathology due to excessive 
inflammation or CSS.
3.4.6 | Are primary immunodeficiency patients at 
increased risk to develop severe COVID-19?
Primary immunodeficient patients are a high-risk group in the 
current pandemic, but to date, it is unknown whether a par-
ticular immunodeficiency poses a higher risk of severe disease. 
International primary immunodeficiency monitoring is being car-
ried out, and few cases have been documented. Patients at higher 
risk are those with complications resulting from their primary im-
munodeficiency, and strict follow-up must be done in those cases. 
A consensus has been established that baseline chronic treatment 
should be continued in those patients if they are asymptomatic 
or mildly symptomatic. Furthermore, recommendations regarding 
primary immunodeficient patients adhere to individual national 
guidelines emphasizing social distancing and strict hygiene meas-
ures. Systematic testing of primary immunodeficient patients is 
not advised; however, recommendations may change as the pan-
demic evolves.88
3.4.7 | What is the role of T regulatory cells in 
COVID-19 pathogenesis?
There are no longitudinal studies analyzing T regulatory cells in 
COVID-19. A limited number of studies have reported decreased 
numbers of circulating T regulatory cells (CD3+ CD4+ CD25+ 
CD127low+) as a part of lymphopenia. Further studies are needed 
to explore their roles in COVID-19 pathogenesis and in controlling 
severe tissue injury or CSS.59,89
3.4.8 | Does metabolic fitness at the cellular and 
individual level affect COVID-19?
Systemic dysregulation of metabolism, such as that seen in obesity 
and diabetes, is a risk factor for SARS-CoV-1 and SARS-CoV-2 in-
fection and for COVID-19 severity.68 These diseases lead to chronic 
systemic inflammation and upregulation of SARS-CoV-2 receptors in 
the lungs and the periphery, and they disturb the glucose and lipid 
metabolism of tissues and immune cells.10,90,91
3.4.9 | What is the pathogenesis of acute 
respiratory distress syndrome (ARDS) in COVID-19?
ARDS is an acute life-threatening inflammation of the lung due to 
infection, trauma, or inflammatory conditions. Excessive inflam-
mation leads to alveolar damage and increased permeability of 
endothelial and epithelial cells. This results in protein-rich fluid 
accumulation in the interstitium and the air space, which causes 
impaired gas exchange and hypoxemia. Reactive oxygen species, 
leukocyte proteases, chemokines, and cytokines also contribute 
to lung injury. The barrier impairment of the lung microvascular 
barrier is central to the pathogenesis of ARDS.92 Pulmonary vas-
cular endothelial injury in association with the presence of the 
intracellular virus and disrupted cell membranes contributes to 
the increase in endothelial permeability. COVID-19 patients with 
ARDS had a histological pattern of diffuse alveolar damage with 
perivascular T-cell infiltration. In addition, alveolar capillary mi-
crothrombi, secondary to endothelial injury, in patients who died 
of COVID-19 may be an important cause of refractory hypoxia in 
ARDS.59,87,93,94
3.4.10 | What are the clinical phenotypes of ARDS 
in COVID-19 patients?
In COVID-19 patients, ARDS is more common in the elderly, those 
with multiple comorbidities, and those with continuing or gradu-
ally progressing neutrophilia and lymphopenia, and a higher level 
of C-reactive protein, lactate dehydrogenase, D-dimer, and proc-
alcitonin.59,87 There are at least 2 clinical phenotypes of ARDS: 1) 
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near-normal pulmonary compliance with isolated viral pneumonia; 
and 2) decreased pulmonary compliance.94,95
3.4.11 | What specific therapies can be suggested 
for ARDS?
Different treatments were suggested for ARDS. Corticosteroid 
treatment is generally not recommended, although widely used in 
critically ill patients. Convalescent plasma (CP) was administered to 
a small number of patients and was associated with virus clearance 
and clinical improvement (Table 2). Low tidal mechanical ventila-
tion, positive end-expiratory pressure, prone positioning ventilation, 
and fluid management guidelines were associated with improved 
outcomes. Extracorporeal membrane oxygenation could be used 
according to the inclusion and exclusion criteria of the EOLIA trial. 
Other potential therapies such as mesenchymal stem cell therapy and 
cytokine inhibitors are still in trials and without definite results.59,96
3.4.12 | Is Bacille Calmette-Guerin (BCG) 
vaccination protective against SARS-CoV-2?
BCG is a live attenuated vaccine that was developed against tuber-
culosis at the beginning of the 20th century. BCG vaccination in-
duces metabolic and epigenetic modifications by enhancing trained 
immunity (innate immunity to subsequent infections).97 It was hy-
pothesized that general BCG vaccination policies adopted by dif-
ferent countries might have impacted the transmission patterns 
and/or COVID-19–associated morbidity and mortality.98,99 BCG 
vaccination in childhood was not protective against SARS-CoV-2 
infection in an Israeli cohort.100 In contrast, randomized controlled 
trials of BCG Danish indicated immunomodulation against pre-
COVID-19 respiratory infections with fewer deaths from sepsis and 
pneumonia. Two clinical Danish trials of BCG Danish (BRACE and 
BCG-CORONA) are evaluating its impact on healthcare workers as 
pertains to COVID-19 infection and severity.101,102
3.4.13 | What is the mechanism underlying 
Kawasaki syndrome in the context of COVID-19?
The mechanisms underlying Kawasaki disease—a generalized vascu-
litis, in young children, of unknown, potentially postviral etiology—
are poorly understood. The rare COVID-19–associated inflammatory 
syndrome also features vasculitic changes, affects older children 
too, and is often only associated with positive SARS-CoV-2 serology, 
but not viral shedding. Its mechanisms need to be elucidated and 
may include postinfectious, antibody, and immune complex–medi-
ated pathology. In adults, there are occasional cases of COVID-19–
associated cutaneous vasculitis, possibly a localized manifestation of 
the disease that leads to severe generalized vasculitis in some chil-
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Chinese cases and the first months of European cases. The season 
of the disease and environmental factors should be considered. The 
Chinese epidemic was mainly from January to March, whereas the 
US epidemic started in mid-March and is still ongoing.
3.4.14 | Which acute-phase reactants are the most 
decisive ones for the follow-up of COVID-19 patients?
Initial results of acute-phase reactants such as C-reactive protein, 
alanine transaminase, lactate dehydrogenase, D-dimer, procalci-
tonin, serum ferritin, and IL-6 on admission were used to evaluate 
the severity and predict the mortality. However, dynamic changes 
in these variables will be more precise in predicting the recovery or 
progression of COVID-19. Continuing or progressively increasing 
levels of C-reactive protein, procalcitonin, D-dimer, and lactate de-
hydrogenase were shown to be associated with a high risk of death 
in severe COVID-19 patients.24,59,106
4  | SEC TION 3:  DIAGNOSIS OF COVID -19
4.1 | What are the principal signs of a SARS-CoV-2 
infection?
Patients with acute respiratory illness (ie, fever and at least one 
sign/symptom of respiratory disease such as cough or shortness 
of breath) and a history of contact with a confirmed or probable 
COVID-19 case during the 14 days before symptom onset. Patients 
with any acute respiratory illness in the context of a pandemic 
should have SARS-CoV-2 infection in their differential diagnosis. 
Special attention should be given to patients with sudden onset 
of anosmia, loss of taste, gastrointestinal symptoms or skin lesions 
without respiratory symptoms, who also have epidemiological 
links.5,24,107
4.2 | What is the importance of smell loss in the 
diagnosis of COVID-19?
Smell loss is now a well-established diagnostic symptom of COVID-
19 and can be present in otherwise asymptomatic patients, making 
it a useful tool in initial diagnosis.108 This has resulted in anosmia to 
be included in the list of symptoms used in early screening tools for 
possible COVID-19 in many international bodies.108
4.3 | What are the prognostic parameters of severe 
COVID-19?
Rapidly progressive respiratory failure and sepsis, elevated serum 
proinflammatory cytokine levels, elevated acute-phase reactants 
(eg, C-reactive protein), cell-free hemoglobin-leukopenia, and mark-
ers of disseminated intravascular coagulation.109
4.4 | What is the most reliable method to determine 
positive COVID-19 cases?
RT-PCR to generate cDNA from SARS-CoV-2 RNA extracted from 
respiratory samples, followed by quantitative PCR (Figure 2).110 
Common gene targets for SARS-CoV-2 include the envelope, nucle-
ocapsid, spike, RNA-dependent RNA polymerase, and ORF1 genes. It 
is recommended to include in the analysis, at least, 2 target genes.111
4.5 | What is the most suitable location to perform 
a swab for SARS-CoV-2 detection via RT-PCR?
Nasopharyngeal and oropharyngeal (throat) swabs are the primary 
specimens for SARS-CoV-2 RT-PCR testing. Lower respiratory tract 
specimens (ie, sputum, endotracheal aspirate or bronchoalveolar 
lavage) may have higher viral loads and be more likely to yield posi-
tive tests (Figure 2). However, these locations carry a high risk of 
aerosolization and therefore should be reserved for severe patients 
with a negative test on an upper respiratory tract specimen and high 
suspicion for lower respiratory tract SARS-CoV-2 infection.112,113
4.6 | Is serology a feasible way to screen for SARS-
CoV-2 infection at a population level?
Serology is useful to determine prior exposure to SARS-CoV-2 
within a given period of time (the length of time following infection 
that one remains positive is unknown) (Figure 2). Detection of anti-
bodies specific to the receptor-binding domain of the spike protein 
indicates neutralization capacity, hence informing better about the 
development of protective immunity.36,110,114
4.7 | What is the relationship between clinical 
manifestations and SARS-CoV-2 seroconversion?
The antibody response occurs later than initiation of symptoms and 
of the detection of viral RNA by RT-PCR in respiratory tract speci-
mens, which usually peaks within the first week of symptom onset 
(Figure 2). Although antibodies to SARS-CoV-2 have been detected 
as early as the first week after symptom onset, seroconversion of 
IgM, IgA, and IgG commonly occurs between the 2nd and 3rd week 
of clinical illness onset. Thereafter, IgM starts to decline, reaching 
low levels by week 5 and almost disappears by week 7, while IgA and 
IgG persist beyond this period.36,38,110,115
4.8 | What are the main approaches for the 
development of a rapid and specific point-of-care 
diagnostic test for COVID-19?
The main approaches include nucleic acid amplification on respira-
tory samples using mobile devices (RT-PCR or isothermal nucleic 
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acid amplification) and viral antigens or host antibodies (viral protein 
fragments) detection using immunoassays.116 However, individual 
tests need validation in large populations before use and their sen-
sitivity, specificity, and positive and negative predictive values have 
to be accurately ascertained. Otherwise, they may lead to COVID-19 
under or over diagnosis, thus undermining the public health efforts 
to control the disease.117
4.9 | There is a high rate of false negatives with 
rapid serology tests for SARS-CoV-2, is there an 
alternative method to determine positive cases?
A high rate of false negatives with antigen point-of-care assays 
may be due to the fact that the majority of patients produce an-
tibodies against SARS-CoV-2 only after the second week after in-
fection (Figure 2).118 Furthermore, an effective antibody response 
is connected with several determinants, comprising severity of the 
disease, age and nutritional status of the patient, medications ad-
ministered, and concomitant infections.117 Nucleic acid amplifica-
tion using RT-PCR directly targeting the virus is not affected by the 
abovementioned limitations.119 However, false-negative real-time 
RT-PCR tests for the diagnosis of SARS-CoV-2 were reported by 
Zhang et al in a retrospective study of 290 hospitalized and con-
firmed COVID-19 patients in Wuhan, China. Forty-one of them ini-
tially tested negative for SARS-CoV-2, and 21/41 tested positive by 
the second real-time RT-PCR test and an additional 13/41 patients 
by the third test. Almost all patients (98%) tested positive by the fifth 
and final test.120 Patients with an initial positive SARS-CoV-2 result 
had an increased risk of progressing to severe cases. Altogether, 
these findings underscore how the timing of the immune response 
influences RT-PCR tests for SARS-CoV-2, and the importance of 
combining RT-PCR and seroconversion data for COVID-19 diagnosis.
4.10 | When can a suspected/confirmed case of 
COVID-19 discontinue home isolation/quarantine?
The decision to discontinue home isolation/quarantine should be 
adapted to specific groups of patients based on factors such as 
symptom severity, healthcare systems' capacity, laboratory diagnos-
tic resources, and local epidemic status. Patients with suspected or 
confirmed symptomatic COVID-19 can discontinue self-isolation/
quarantine if all the following 4 conditions are met: (a) resolution 
of fever (without the use of fever-reducing medications) for at least 
3 days; (b) clinical improvement in respiratory symptoms (eg, cough, 
shortness of breath) for at least 3 days; (c) at least 8 days has passed 
since the onset of symptoms for mild cases or at least 14 days for 
severe cases and immunocompromised patients; and (d) 2 negative 
RT-PCR tests from respiratory specimens taken 24 hours apart. If 
there is limited or no testing capacity, the combined symptom/test-
based strategy should be reserved to hospitalized COVID-19 cases 
and healthcare workers, whereas for mild or asymptomatic COVID-
19 cases (suspected or confirmed), the symptom-based strategy 
(condition a) AND b) AND c) without laboratory testing is considered 
acceptable to end the self-isolation period.121
5  | SEC TION 4:  ORGANIZ ATION OF 
ALLERGY OUTPATIENT CLINIC S AND 
L ABOR ATORIES DURING THE COVID -19 
PANDEMIC
5.1 | What are the emergency measures in an 
ongoing allergy clinic during the COVID-19 pandemic?
Strategies for risk minimization should be elaborated, harmonized, 
and followed as such in allergy clinics, centers, and practices.122 In the 
EAACI/ARIA Position Paper by Pfaar et al,123 experts in the field have 
developed practical recommendations for optimizing allergic patients’ 
care while ensuring the safety of all healthcare professionals (Figure 3). 
General guidance from national health authorities should be strictly 
followed (ie, World Health Organization, WHO; European Centre for 
Disease Prevention). In-person consultations should be minimized 
to the lowest necessary level and triaged by telemedicine whenever 
possible (Figure 4).124 Special attention should be paid to data pro-
tection in adherence to national data security and protection laws. 
Nondelayable diagnostic and therapeutic measures should strictly 
follow reasonable preventive measures. Several specific considera-
tions regarding diagnostic and therapeutic measures are important in 
different allergic diseases (Figure 5). Moreover, sociopsychological as-
pects play a fundamental role in the care of allergic patients during the 
current pandemic and should be especially recognized and followed. 
Stress caused by isolation and stigmatization due to allergic symptoms 
may amplify the development of allergic symptoms.125
5.2 | Is previsit specific telephonic triage useful to 
identify patients possibly infected with SARS-CoV-2?
Virtual doctor consultations have been regarded as an alternative to 
on-site clinical encounters and are increasing during the COVID-19 
pandemic.123 Initially, previsit telephonic communication is helpful 
to screen for patients with potential SARS-CoV-2 infection.126 The 
epidemiological history should be investigated to determine whether 
patients have fever or respiratory symptoms. In addition, pre-visit–
specific triage improves the efficiency of the patient's visit, thus 
reducing the length of stay in the hospital. To reduce face-to-face 
meetings, physicians can train some patients to self-treat at home 
based on the diagnosis obtained through a telephone consultation 
(Figure 4).
5.3 | Should every allergic patient be tested for 
SARS-CoV-2 prior to coming to the clinic?
A strict screening protocol is needed to identify SARS-CoV-2–in-
fected patients (Figure 4). Ideally, only SARS-CoV-2–negative 
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patients (diagnosed via RT-PCR and/or rapid test) should come to 
the clinic. In places where systematic testing is unavailable, at least 
normal temperature and negative epidemiological history should 
be mandatory to proceed to the outpatient departments. Patients 
with a body temperature higher than 37.3ºC should have additional 
screening examinations, including routine blood tests, chest com-
puted tomography scanning, and even throat swabs for SARS-CoV-2 
RT-PCR testing.127
5.4 | What should be considered when performing 
diagnostic procedures during the COVID-19 pandemic?
The indication and urgency of the tests for diagnosis should be consid-
ered. Contraindications for skin, provocation, and lung function tests 
can be explained beforehand to the patient, which helps to avoid un-
necessary in-person consultations.123 Any test generating aerosol par-
ticles should be avoided because it is considered high risk (Figure 4).
F I G U R E  3   Preventive measures for 
SARS-CoV-2 infection and control for 
healthcare providers. PPE, personal 
protective equipment (medical mask, 
eye/facial protection, gloves, long 
sleeve gown, and waterproof apron). 
*Adequately ventilated room: natural 
ventilation with airflow of at least 160 L/s 
per patient, or negative-pressure rooms 
with at least 12 air changes per hour. 
Controlled direction of airflow when using 
mechanical ventilation (adapted from 
“WHO: Infection prevention and control 
during health care when COVID-19 is 
suspected”)126
F I G U R E  4   Organization of an allergy 
clinic during the COVID-19 pandemic. 
Patients should be triaged to determine 
those in need of face-to-face consultation 
and those at risk of infection with SARS-
CoV-2. Telehealth should be prioritized 
in allergy clinics. Procedures at high risk 
of generating airborne particles should 
be avoided. Patients should be motivated 
to notify their healthcare professionals 
in case of exacerbations or changes in 
their usual symptoms. FeNO, fractional 
concentration of exhaled nitric oxide; IOS, 
impulse oscillometry
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5.5 | What kind of procedures should be performed 
in biosafety level (BSL)-2 and BSL-3 laboratories 
during the COVID-19 pandemic?
Personal protective equipment (PPE) must be used when collect-
ing biological samples. Biological samples collected on-site from 
suspected or confirmed COVID-19 patients (eg, antibody assays, 
RNA isolation, flow cytometry) should be processed following BSL-2 
practices. During and after the COVID-19 pandemic, the usage of 
BSL-2 facilities is mandatory for all newly arriving patient samples 
to prevent spreading the disease. Research procedures involving 
SARS-CoV-2 isolation or culture should be conducted in a BSL-3 
facility.123,128
6  | SEC TION 5:  COVID -19 AND ALLERGIC 
DISE A SE
6.1 | Do patients with allergic diseases have a higher 
risk of developing severe COVID-19?
Patients with common allergic diseases do not develop distinct 
symptoms or severe outcomes. Allergic children show a mild course 
similar to nonallergic children.5 In a recent study of 182 hospitalized 
children, 43 of them were reported with allergies. Allergic rhinitis 
was the most prevalent allergic disease (83.7%), followed by drug 
allergy, atopic dermatitis, food allergy, and asthma. In this study, al-
lergic children showed a reduced increase in acute-phase reactants, 
procalcitonin, D-dimer, and aspartate aminotransferase levels com-
pared with all patients. There were no deaths in allergic children in 
that study.13290
6.1.1 | Allergic rhinoconjunctivitis
What is the strategy to distinguish between hay fever/pollen allergy 
and COVID-19 infection?
Clinical history is very helpful to identify seasonality- and exposure-
related symptoms driving the diagnosis of pollen-induced allergic 
rhinitis. An atopy test (in vivo or in vitro) reinforces the diagnosis. 
However, COVID-19 can be superimposed on allergic rhinitis symp-
toms.123 Symptoms such as fever, fatigue, and sudden loss of smell 
are suggestive of COVID-19 and should be closely monitored.
What is the recommended mask to prevent allergic rhinitis 
symptoms during the COVID-19 pandemic?
N95 facial masks have been proven useful in reducing allergen ex-
posure by blocking pollen access to nose and mouth. On the other 
hand, surgical masks do not protect against inhalation of small air-
borne contaminants and are not designed to seal tightly against 
F I G U R E  5   Practical considerations for allergy therapies during the COVID-19 pandemic. Continuation of second-generation H1-
antihistamines for the treatment of allergic rhinitis and urticaria, topical corticosteroids for atopic dermatitis, nasal corticosteroids for allergic 
rhinitis, and inhaled corticosteroids for asthma. Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) for respiratory 
and venom allergies should be continued in noninfected individuals and patients recovered from COVID-19, and it should be suspended in 
patients diagnosed with COVID-19 or suspected of SARS-CoV-2 infection until resolution of COVID-19 is established. Biologicals should be 
continued, if possible as home self-administration, in patients noninfected or recovered from COVID-19, and they should be suspended in 
patients diagnosed with COVID-19 or suspected of SARS-CoV-2 infection until resolution of COVID-19 is established
     |  2519RIGGIONI et al.
the user's face; hence, the contaminated air can pass through the 
gaps.130
Does allergic rhinitis impact the susceptibility of SARS-CoV-2 
infection?
There are no conclusive data on the impact of allergic rhinitis on 
COVID-19 susceptibility.131 A recent study with 24 allergic rhinitis 
patients demonstrated a reduction of ACE2 expression in nasal brush 
samples following an allergen challenge.54 Also, this study reported 
lower ACE2 expression in the epithelium of asthmatic patients. On the 
other hand, TMPRSS2 is highly upregulated by type 2 inflammation 
through the action of IL-13.58 Therefore, further studies are necessary 
to determine whether allergic rhinitis patients have an altered risk of 
SARS-CoV-2 infection as compared to nonallergic individuals.
Are allergic rhinitis patients at higher risk of severe COVID-19?
Although limited, the available evidence suggests that, compared 
with nonallergic individuals, allergic rhinitis patients are not at higher 
risk of developing severe COVID-19. In a Chinese cohort of 140 hos-
pitalized COVID-19 adult patients, allergic rhinitis and asthma were 
not risk factors for SARS-CoV-2 infection.24 A similar finding was 
also reported in children. In a recent study addressing the clinical 
characteristics of 182 children with COVID-19, 43 of them had an 
allergic condition, which was mainly allergic rhinitis (83.7%). In this 
study, allergic children exhibited a disease progression comparable 
to that of nonallergic children.129 Prospective trials are urgently 
needed.
What are the recommendations for patients suffering from severe 
conjunctivitis and keratoconjunctivitis during the COVID-19 
pandemic?
Patients should continue baseline treatment as established by their 
physician and current guidelines. According to a panel of experts, 
low-dose corticosteroids or antiallergic eye drops continue to be the 
first line of treatment for allergic conjunctivitis during the current 
pandemic. Although there is no evidence on the possible effect of 
SARS-CoV-2 on patients using ocular immunomodulating drugs, in 
patients with vernal keratoconjunctivitis and allergic keratoconjunc-
tivitis, the use of local immunomodulatory treatment is considered 
safe in noninfected patients and should be monitored closely in 
those with active infection. The use of systemic immunosuppres-
sants for severe COVID-19 cases should be considered on an indi-
vidual basis.132
What are the recommendations for patients suffering from allergic 
rhinitis during the COVID-19 pandemic?
There is no scientific evidence that treatments for allergic rhinitis ei-
ther increase susceptibility to SARS-CoV-2 infection or the severity 
of COVID-19. Therefore, allergen avoidance measures, nasal saline 
douches, and background controller therapies recommended by cur-
rent guidelines for allergic rhinitis, such as nasal corticosteroids or 
second-generation H1-blockers, should be continued as prescribed, 
both in noninfected and in COVID-19–diagnosed patients.123,131 
Such treatments can help reduce the spreading of an eventual SARS-
CoV-2 infection by targeting characteristic clinical features of allergic 
rhinitis, such as sneezing and rhinorrhea, and might prevent unnec-
essary visits to physicians and emergency departments. Specific rec-
ommendations apply to patients with allergic rhinitis treated with 
allergen immunotherapy (AIT) or biologics. These therapies should 
be suspended in COVID-19–diagnosed patients or suspected cases 
for SARS-CoV-2 infection until resolution of the disease is estab-
lished (eg, via a negative SARS-CoV-2 test in connection with clinical 
recovery) (Figure 5).123,133
6.1.2 | Chronic rhinosinusitis and other upper 
respiratory tract diseases
Is there a difference in the mechanism driving anosmia in chronic 
rhinosinusitis and SARS-CoV-2 infection?
The loss of smell in chronic rhinosinusitis is caused by type 2 inflam-
mation of the olfactory epithelium.134 In COVID-19, the exact mech-
anism of potential olfactory neuropathy is still unclear.135 However, 
a study found that sustentacular cells of the olfactory epithelium 
express ACE2 and TMPRSS2, which enable SARS-CoV-2 entry and 
may subsequently impair the sense of smell.136
Is intranasal corticosteroid treatment recommended for patients 
with COVID-19 that present with loss of smell?
A considerable percentage of COVID-19 patients experience loss of 
smell as an early sign of the disease.108 In many patients, smell recov-
ers in 1-2 weeks, and there is no indication that intranasal corticos-
teroid treatment has a positive impact on the recovery.137 On the 
other hand, there is no evidence, suggesting that this treatment has a 
negative impact on symptomatology and/or development of COVID-
19. Consequently, it is recommended to continue regular intranasal 
corticosteroid treatment for chronic rhinosinusitis (Figure 5).123,131
What are the recommendations for performing nasal endoscopy 
surgery in COVID-19 patients?
Diagnostic procedures involving upper airway manipulation, such as 
nasal endoscopy, should be considered high risk for viral transmission. 
Before clinical examination, it is recommended to question all patients 
about contact with confirmed COVID-19 patients, fever, respiratory 
symptoms, and recent sudden loss of smell and/or taste. During nasal 
endoscopy, distance between the endoscopist and patient can be 
maximized by using a tower with a camera, screen, and light source, 
rather than using an eyepiece. Also, manipulations should be limited 
if possible (ie, nasal inspection vs debridement with suction and/or 
forceps). The use of local anesthetic sprays can be replaced by alter-
natives such as soaked pledgets because atomized anesthesia can 
aerosolize the virus.138 Given that the COVID-19 status of patients 
consulting the outpatient rhinology clinic is often unknown and the risk 
of transmission through clinical procedures is high, wearing adequate 
PPE is mandatory.123,139 For all surgical cases, preoperative screening 
of the COVID-19 status of the patient is recommended to adapt the 
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PPE accordingly. In case of an emergency where COVID-19 screening 
would imply an unacceptable time delay, the patient should be consid-
ered as COVID-19–positive and PPE used (Figure 3).138
Is corticosteroid treatment before surgery for chronic rhinosinusitis 
with nasal polyps recommended during the pandemic?
The use of intranasal corticosteroids does not seem to have a negative 
impact on symptoms and/or development of COVID-19.131 Therefore, 
intranasal corticosteroid treatment should be continued periopera-
tively if possible. The use of corticosteroids either during an exacerba-
tion or perioperatively should be carefully considered on a “per-patient” 
basis. Recent guidance from the WHO has advised against the use of 
systemic corticosteroids if COVID-19 is suspected due to concerns 
that these agents may impair innate antiviral immune responses.140
What are the treatment recommendations for COVID-19 children 
with chronic otitis media with effusion?
Chronic otitis media with effusion is a common childhood disease 
usually with the absence of signs or symptoms of acute ear infection. 
It is therefore preferable to treat COVID-19 first and delay elective 
surgery. The indication and choice of surgery (eg, tympanostomy 
tubes and/or adenoidectomy) should comply with the professional 
Clinical Practice Guidelines.141,142
6.1.3 | Asthma
How can an asthma exacerbation be differentiated from a SARS-
CoV-2 infection?
An asthma exacerbation is difficult to differentiate from COVID-19 
ARDS or pneumonia by the patient, especially if it is triggered by 
rhinovirus, or other common respiratory viruses, because both con-
ditions have dry cough and dyspnea. The British Thoracic Society 
advises patients with asthma experiencing fever, fatigue, and loss 
of taste or smell to alert their physician as these are indicative of 
COVID-19.143 The distinction can be made by the physician based on 
the presence of wheeze, which is generally (but not always) absent in 
COVID-19 pneumonia, as well as high-resolution chest tomography 
and viral diagnostic tests.123
Are COVID-19 patients with asthma at a higher risk of severe 
COVID-19 than the general population?
Patients with controlled asthma are not at higher risk of severe infec-
tion than the general population.52,53 ACE2 expression was shown to 
be decreased in patients with allergic asthma54 and in those receiv-
ing inhaled corticosteroids.144 On the other hand, ACE2 expression 
in asthmatic patients was increased in African Americans and in men, 
and associated with diabetes,54 and type 2 inflammation in children 
is associated with increased expression of TMPRSS2.58 It is clear 
though that uncontrolled asthma is a risk factor for severe COVID-
19; thus, all efforts should be focused on treating asthma by regular 
use of controller medication, including inhaled corticosteroids and 
biologicals.52,145,146
Are patients on inhaled corticosteroids maintenance treatment at 
higher risk of infection or more severe COVID-19?
There is no evidence available that patients on inhaled corticos-
teroids are at higher risk of COVID-19 infection or of more severe 
symptoms than the general population. It is strongly advised by in-
ternational scientific societies that patients continue with their rou-
tine control medication including inhaled corticosteroids during the 
pandemic (Figure 5).131,147
Corticosteroids inhibit rhinovirus and RSV-induced cytokine release 
in vitro. Do inhaled corticosteroids have a protective effect against 
SARS-CoV-2?
Recent evidence indicates that inhaled corticosteroid treatment re-
duces the expression of viral membrane receptors used to infect the 
human airways in a dose-dependent manner.144 On the other hand, 
the immune suppression exerted by corticosteroids may impair an-
tiviral responses.140 However, there are no clinical studies investi-
gating the effect of inhaled corticosteroid on SARS-CoV-2 infection 
rates.
Given the current restrictions, should spirometry and other lung 
function tests for initial asthma diagnosis be performed?
Spirometry is essential for the diagnosis of new asthma cases as 
stated by the Global Initiative for Asthma guidelines. Therefore, 
it should be conducted, but under special conditions (negative-
pressure chamber, etc) and only in areas with low SARS-CoV-2 
infection incidence. Healthcare providers performing lung func-
tion testing need to wear maximum PPE (filtering facepiece parti-
cles 2 or 3 face mask, goggles, or disposable face shield covering 
the front and sides of the face, clean gloves, and clean isolation 
gowns), and the spirometer devices should be properly disinfected 
between patients (Figure 3).148 An alternative, less precise, is mon-
itoring morning and evening peak expiratory flow variability over 
a week.149,150
Should routine spirometry and lung function control be performed 
in asthmatic patients during the COVID-19 pandemic?
The Global Initiative for Asthma guidelines state that routine 
spirometry should be avoided, especially in high-risk areas of 
COVID-19 transmission. If spirometry needs to be performed, 
maximum PPE should be used (Figures 3 and 4).147 The treatment 
of asthmatic patients can be monitored using personal devices 
measuring forced expiratory volume and peak expiratory flow. 
Many of these devices are equipped with remote transmission 
functions and thus are amenable for the telemedicine manage-
ment of patients.151
Should asthma exacerbations be treated with oral corticosteroids 
during the COVID-19 pandemic?
There is no evidence suggesting that the current approach to treat 
asthmatic patients during an exacerbation should change dur-
ing the COVID-19 pandemic. Moreover, there is no proof that a 
short course of systemic corticosteroids impacts the evolution of 
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COVID-19. Thus, oral corticosteroids should be given as usual for 
the treatment of an asthma exacerbation (Figure 5).143,147In the 
few cases in which patients are treated with long-term oral corti-
costeroids in addition to their high-dose inhaled corticosteroids, 
this should be continued in the lowest dose possible to prevent 
exacerbations.147 The cause of the asthma exacerbation should be 
studied thoroughly to rule out potential exacerbations due to viral 
infections.88
What is the safest way to administer a medication that creates 
airborne particles during the COVID-19 pandemic?
The preferred treatment is a pressurized metered-dose inhaler 
with a spacer. Each patient should have an individual spacer, and 
this should not be shared at home. The use of nebulizers should be 
avoided when possible because they increase the risk of disseminat-
ing viral particles, which could affect other patients and healthcare 
personnel.147
What is the correct way to manage anti-IgE treatment during the 
COVID-19 pandemic?
Anti-IgE treatment with omalizumab (or other biologics indicated 
for asthma) should be continued in noninfected patients. Self-
administration devices at home, whenever this option is available, are 
preferred, to minimize face-to-face contact in the clinic. In infected 
patients, omalizumab administration should be delayed until com-
plete clinical recovery and viral clearance is achieved (Figure 5).49,152
CSS in COVID-19 patients is characterized by increased IL-6 levels. 
Given that an IL-6/Th17 endotype is associated with severe asthma 
in obese patients, are obese asthmatic patients more likely to 
develop severe COVID-19?
Obesity, as part of the metabolic syndrome, increases the risk of 
severe COVID-19. This is due to the pre-existent systemic low-
grade inflammation and increased expression of SARS-CoV-2 
entry receptors (ACE2, TMPRSS2, and CD147).153,154 Obese pa-
tients tend to have worse asthma control, increased hospitaliza-
tions and suboptimal response to standard controller therapy. 
Thus, both difficult-to-control asthma and underlying metabolic 
syndrome are risk factors for severe COVID-19. The IL-6/TH17 
endotype encountered in late-onset obese asthma might be an ad-
ditional risk factor.155,156
6.1.4 | Atopic dermatitis and other skin lesions
What are the dermatological manifestations of COVID-19?
The dermatological manifestations of COVID-19 range from an un-
specific macular erythematous rash, urticarial lesions, chickenpox-
like vesicles, and acro-ischemic lesions.157,158 They can result from 
local inflammation due to circulating immune complexes or from sys-
temic manifestations leading to vasculitis and thrombosis.159 These 
patients are also at increased risk of drug hypersensitivity lesions 
(Figure 6).160
Are patients with epithelial barrier disorders at higher risk of skin 
complications?
There is no evidence that patients with barrier defects such as atopic 
eczema have a higher risk for SARS-CoV-2 infection or skin compli-
cations during COVID-19. However, patients with atopic dermatitis 
may be on systemic immunosuppressants and should be monitored 
closely. Optimal topical treatment regime should also be encouraged 
in all patients.161
Does frequent hand washing for COVID-19 prevention increase the 
risk of atopic dermatitis?
Hand hygiene procedures are pivotal to prevent self-infection and 
virus spreading. However, extensive water contact enhances dry 
skin, disturbs the commensal microbiota, and leads to barrier dis-
ruption in healthy individuals. Moreover, it exacerbates diseases 
with an intrinsic barrier defect such as atopic dermatitis.162,163 
Effective skin care after hand hygiene is therefore essential to 
prevent barrier disruption and sensitization events. Here, emol-
lients containing hyaluronic acid, vitamin E, ceramide, or urea are 
recommended.164
Does dupilumab treatment increase SARS-CoV-2 infection 
susceptibility?
Dupilumab is approved for the treatment of moderate-to-severe 
atopic dermatitis. First data from Italy on dupilumab-treated nonin-
fected in high-epidemic areas, and current evidence from dupilumab 
trials, suggest no negative effect of dupilumab regarding viral infec-
tions165 with reports on a reduced number of herpes simplex super-
infections and less bacterial superinfections.166-168
Should dupilumab treatment for atopic dermatitis patients be 
suspended or modified during the COVID-19 pandemic?
The current EAACI statement on the usage of biologicals in the 
context of COVID-19 advices no change in therapy in noninfected 
individuals and to withhold/delay the application of biologicals for 
a minimum of two weeks or the resolution of the disease in case of 
SARS-CoV-2 infection (Figure 5).49 This is based on expert opinion 
in light of missing data and may be adapted if more information be-
comes available.
Should patients presenting with acro-vasculitis be studied for 
coagulation defects and considered for preventive therapy even if 
they are asymptomatic?
Acro-ischemic lesions on toes and fingers have been identified in a 
subgroup of COVID-19 patients.24,169 The data available are scarce, 
and it is unclear whether preventive or active anticoagulation should 
be initiated. However, acro-ischemic lesions could predate other 
SARS-CoV-2 symptoms in children and young adults.
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6.1.5 | Drug hypersensitivity
How to differentiate skin lesions caused by COVID-19 itself from 
those secondary to drug hypersensitivity during the treatment of 
the disease?
COVID-19-induced skin lesions can be related to thrombovascu-
lar events (ie, petechiae, acro-ischemia, dry gangrene) or to typi-
cal viral infections (ie, erythematous rash, urticaria, maculopapular 
exanthema).160 Drug hypersensitivity has to be considered as a dif-
ferential diagnosis, mainly in the second group, being a distinction 
difficult during the acute phase. Diagnosis relies mostly on clinical 
observations. In that regard, an accurate chronology of the reaction 
and the drug exposure timeline is very informative.62 Laboratory and 
histopathological findings may also help.
Of the drugs being assessed for COVID-19 treatment, which 
ones are more immunogenic or associated with hypersensitivity 
reactions?
Immunomodulatory drugs (including azithromycin), hydroxychloro-
quine/chloroquine, and IFNs are the ones most frequently involved 
F I G U R E  6   Cutaneous manifestations of COVID-19. Several skin manifestations can be potentially associated with the disease: (1) Local 
skin inflammation is often connected with the antibody response toward viral nucleotides and presents as morbilliform rash, maculopapular 
lesions, vesicular exanthems, urticaria, and erythema multiforme; (2) systemic inflammation is associated with vasculitis and thrombosis, 
which are shown as peripheral cyanosis, livedo reticularis, and chilblain-like lesions; and (3) hypersensitivity reactions to drugs may 
occur more often during the pandemic due to the increased use of drugs and drug interactions, which can result in morbilliform rash, 
erythroderma, exanthematous pustulosis, and anaphylaxis
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in hypersensitivity reactions. Most reactions are nonimmediate, and 
further studies are required to clarify whether this increased fre-
quency is caused by the drug immunogenicity or simply derives from 
a greater consumption as compared to other treatments.160
Should drug provocation testing be performed during the COVID-19 
pandemic?
Drug provocation tests are not recommended because reactions 
can occur during the tests, including the generation and spread-
ing of virus-containing aerosols. However, they may be considered 
after careful risk-benefit assessment in cases of urgent need, such as 
chemotherapy in cancer patients, perioperative drugs and radiocon-
trast media in subjects needing urgent procedures, and antibiotics if 
no effective alternative drug is available.123
6.1.6 | Handling of AIT during the 
COVID-19 pandemic
Should AIT in allergic rhinitis and/or asthma patients be interrupted 
to reduce visits to healthcare centers during the COVID-19 
pandemic?
Most AIT products authorized for use in Europe indicate that AIT 
should be discontinued in case of infection; the same principle will 
apply to the COVID-19 pandemic. In patients on subcutaneous or 
sublingual AIT, who are diagnosed with COVID-19, those suspected of 
SARS-CoV-2 infection or symptomatic patients with a positive contact 
to SARS-CoV-2 individuals, AIT should be interrupted until the patient 
has recovered. In patients not infected or who have recovered from 
the infection, AIT could be continued (Table 3). These recommenda-
tions are conditional and could change as clinical data evolve.123,133
Should venom AIT be stopped during the COVID-19 pandemic?
AIT should continue in noninfected patients or those recovered from 
COVID-19 (Figure 5). This is especially important in patients with 
life-threatening conditions such as venom allergy. It is possible to 
extend the intervals between vaccines during subcutaneous AIT, as 
done for inhalant allergens, to minimize visits to the allergy clinic. If 
venom AIT was stopped due to SARS-CoV-2 infection, it is unclear 
when it should be reinitiated because data from convalescent pa-
tients are scarce.133
What is the correct way to manage oral immunotherapy for food 
allergy during the COVID-19 pandemic?
In patients diagnosed with COVID-19 or cases with suspected 
SARS-CoV-2 infection, oral immunotherapy dosing should continue 
as indicated in the dosing plan and in coordination with the treat-
ing physician. Oral immunotherapy can be continued in noninfected 
patients and those who have recovered from COVID-19 (Figure 5). 
In areas with high level of SARS-CoV-2 community transmission, vis-
its to the allergy clinic for oral immunotherapy up-dosing should be 
postponed.123,133
7  | SEC TION 6:  TRE ATMENT OF COVID -19
7.1 | Is it more important to treat the viral infection 
or the CSS in COVID-19 patients?
COVID-19 treatment entails 3 main approaches: (a) antiviral; (b) sys-
temic anti-inflammatory and immunologic; and (c) symptomatic and 
supportive treatment. The patient's viral load detected at the onset 
of COVID-19 is associated with mortality. Consequently, SARS-
CoV-2–specific antiviral treatments, once licensed, are expected 
to be central to COVID-19 treatment. Systemic anti-inflammatory 
treatments are essential in severe COVID-19 cases with CSS as the 
latter is a decisive risk factor for mortality, multiorgan failure, ARDS, 
and disseminated intravascular coagulation. For these reasons, 
COVID-19 treatments must induce quick viral clearance while pre-
cluding systemic inflammatory syndromes.59
7.2 | In home-treated mild COVID-19 patients, 
what are the alarm symptoms to seek hospital 
assistance?
These patients are generally on symptomatic treatment. They 
need to look out for symptoms suggesting hypoxia or pneumonia, 
such as shortness of breath, deep shallow breathing, chest pains 
or persistent tachycardia. Special attention needs to be given to 
those with risk factors for disease progression, such as patients 
older than 65 years, cardiac or pulmonary comorbidities, and 
immunosuppression.170,171
Continue SCIT or SLIT Noninfected individuals
• Asymptomatic patient without suspicion for SARS-CoV-2 infection 
and/or contact with SARS-CoV-2–positive individuals
Patients recovered after COVID-19 infection
• Patient with negative test result (RT-PCR)
• Patient after an adequate quarantine
• Patient with serum IgG to SARS-CoV-2 without virus-specific IgM
Stop SCIT or SLIT • Symptomatic patients with exposure or contact to SARS-CoV-2-
positive individuals
• Patients with positive test results (RT-PCR)
Abbreviations: AIT, allergen immunotherapy; RT-PCR, reverse transcription-polymerase chain 
reaction; SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy.
TA B L E  3   Recommendations for AIT 
during the COVID-19 pandemic. Based on 
EAACI-ARIA guidelines133
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7.3 | Which of the COVID-19 patients would benefit 
from anticoagulant treatment?
Prophylactic low molecular weight heparin, or heparin, has been 
recommended by the WHO in severe to critically ill COVID-19 pa-
tients.140 However, the International Society on Thrombosis and 
Haemostasis recommended that all hospitalized COVID-19 patients, 
not just those in ICU, should receive prophylactic low molecular 
weight heparin in the absence of contraindications.172
7.4 | Does systemic corticosteroid treatment 
at the initial phases of COVID-19 prevent the 
immunopathology seen in severe cases?
During the SARS outbreak in 2003, corticosteroids did not change 
the course of the viral infection and delayed viral clearance.173 On 
the other hand, a retrospective study on SARS patients in Hong 
Kong suggested a better survival rate in patients treated with 
prednisolone for milder pneumonia or methylprednisolone in more 
severe cases.174 Recently, Chinese experts stated that, in COVID-
19 patients, systemic corticosteroids should be considered on in-
dividual indications in a low-to-moderate dose and for no longer 
than a week.175 The National Institutes of Health in their COVID-19 
Treatment Guidelines advises against the use of systemic corticos-
teroids in noncritically ill patients.176
7.5 | Is there enough evidence to support that 
current COVID-19 treatments are better than 
placebo in terms of symptoms’ severity and 
aftermath?
There are over 170 clinical trials on COVID-19 treatment registered 
now in the international databases, and very few have been com-
pleted. Currently promoted pharmacological treatments are, at the 
most, based on anecdotic data collected in small numbers of COVID-
19 patients. These studies did not satisfy evidence-based medicine 
criteria, but caught general attention through news media, for exam-
ple, hydroxychloroquine (see below).
7.6 | Tocilizumab has been used for ICU patients 
with severe COVID-19, what is the rationale?
Tocilizumab is a humanized monoclonal antibody specific for IL-6R, 
and it is approved for the treatment of rheumatoid arthritis. A posi-
tive response to tocilizumab points toward an imbalanced innate im-
mune response in severe COVID-19. Luo et al177 reported that of 
the 15 patients treated with tocilizumab, 7 of them critically ill, and 
11 of the patients recovered within a week. Prompt resolution of 
symptoms and encouraging results have also been reported in un-
controlled or retrospective trials.178-189
7.7 | What lessons learned from the previous SARS-
CoV and MERS-CoV viruses have proven useful to 
identify therapeutic targets for COVID-19?
These zoonotic beta-coronaviruses share structural and genomic 
similarities that are useful to understand COVID-19. SARS-CoV and 
MERS-CoV have lower transmission rate, shorter incubation time, 
and higher fatality rates than SARS-CoV-2. In all of them, the spike 
protein plays a key role in infection via ACE2 binding; hence, it is a 
clear therapeutic target. Potential treatments already used for SARS-
CoV and MERS-CoV include remdesivir, chloroquine, tocilizumab, 
and CP, among others. However, none of them have been tested in 
robust clinical trials (see below Section 9). Lessons in epidemiologi-
cal surveillance and isolation measures have also proven useful.190
7.8 | What is the impact of nonsteroidal anti-
inflammatory drug use in symptomatic COVID-19 
patients?
Fang et al191 suggested that there is ACE2 overexpression upon 
treatment with ACE inhibitors, thiazolidinediones and ibuprofen. 
There were concerns pertaining to the use of nonsteroidal anti-in-
flammatory drugs in COVID-19 patients. The European Medicines 
Agency clarified that no scientific evidence established a link be-
tween ibuprofen, or other nonsteroidal anti-inflammatory drugs, and 
a risk to worsen COVID-19.192
8  | SEC TION 7:  CLINIC AL TRIAL S AND 
DRUG DISCOVERY IN COVID -19
8.1 | What are the main recommendations for 
organizing clinical trials during the COVID-19 
pandemic?
Adaptations for clinical trials during the pandemic must include all con-
cerned parties such as patients, clinical research organizations, clinical 
trial units, ethical committees, regulatory authorities, and sponsors. 
Major changes must be approved by the responsible ethical commit-
tee and covered by the informed consent form. Additional risks to par-
ticipants should be addressed in the benefit-risk assessment section 
of the protocol, together with risk reduction measures (Figure 3).123 
Patients who continue study participation should postpone site visits 
or, whenever possible, be replaced by remote data assessment via tel-
emedicine under strict observation of data protection regulations. If 
needed, the duration of stay in the clinic should be limited and travel 
arranged to include alternatives to local public transport. The initiation 
of new clinical trials should be critically evaluated. The International 
Committee of Medical Journal Editors has clarified that in the event 
of public health emergencies such as COVID-19, information relevant 
for the public health should be disseminated because this would not 
preclude subsequent publication in a scientific journal.133
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8.2 | What are the main recommendations for 
clinical trial design during the COVID-19 pandemic?
Hundreds of registered clinical trials regarding potential therapies for 
COVID-19 are currently open in international registries. The study de-
signs and outcomes are often divergent and based on a single center's 
experience or compassionate use of the candidate treatments. To im-
prove the quality of the evidence and secondary analysis, the scientific 
community should lead multicenter, multi-arm, and highly powered 
clinical trials and foster the global sharing of knowledge on the COVID-
19. This approach would empower the generation of high-quality data 
on efficacy and safety of potential therapies for COVID-19.193
8.3 | What are the main drugs under investigation 
that block SARS-CoV-2 cell entry?
There are drugs that interfere with ACE2 and TMPRSS2, which are 
molecules used by the virus to enter the cell.9,194 For example, camo-
stat mesylate is a clinically proven serine protease inhibitor with affin-
ity for TMPRSS2. It has shown activity against SARS-CoV-2 in human 
lung Calu-3 cells.9 Several drugs that target virus internalization are 
being investigated, including chloroquine phosphate and hydroxychlo-
roquine, which have shown limited efficacy in humans and raised con-
cerns due to side effects (see below).195 It also includes a combination 
of cepharanthine (an anti-inflammatory alkaloid), selamectin (an aver-
mectin used as an anti-helminthic and parasiticide drug in veterinary 
medicine), and mefloquine hydrochloride (used for the prophylaxis 
and treatment of malaria),196 and meplazumab197 (see below), among 
others. Although still at the experimental level, a clinical-grade human 
recombinant ACE2 has shown efficacy to block SARS-CoV-2 growth in 
kidney epithelial cells (Vero cells) (Figure 1).198
8.4 | What are the main drugs under investigation 
that block SARS-CoV-2 replication?
Drugs designed to inhibit the viral replication machinery may be ef-
fective against SARS-CoV-2. For example, remdesivir inhibits viral 
RNA polymerases, which prevents SARS-CoV-2 replication (see 
below). It is uncertain whether lopinavir-boosted ritonavir and other 
antiretrovirals improve clinical outcomes or prophylaxis among pa-
tients at high risk of SARS-CoV-2 infection.199 Additional potential 
candidates include other broad-spectrum antiviral drugs such as ar-
bidol and favipiravir and phytochemicals with antiviral activity such 
as resveratrol (Figure 1).196
8.5 | What is the clinical evidence supporting a 
beneficial effect of remdesivir in COVID-19 patients?
In a cohort of severe COVID-19 patients, compassionate use of 
remdesivir showed clinical improvement in 68% of patients (36 out 
of 53).200 Of note, a double-blind, randomized, placebo-controlled 
trial of intravenous remdesivir was conducted in 1,063 adults hos-
pitalized with COVID-19 with evidence of lower respiratory tract 
involvement; remdesivir was superior to placebo in shortening the 
time to recovery in adults hospitalized with COVID-19 and evidence 
of lower respiratory tract infection.201 Furthermore, in a study of 5 
HIV-positive hospitalized patients with severe COVID-19, three of 
them were given lopinavir-boosted ritonavir and 2 darunavir-boosted 
cobicistat for 14 days. Four patients recovered, and 1 remained hos-
pitalized.202 On the other hand, in a study with 99 hospitalized adult 
patients with severe COVID-19, no benefit beyond standard care 
was observed with lopinavir-boosted ritonavir treatment twice daily 
for 14 days.203
8.6 | Is meplazumab a potential therapy for 
COVID-19 patients?
Meplazumab is a CD147-specific humanized monoclonal antibody 
that has been shown to prevent SARS-CoV-2 infection of fibroblasts 
(VeroE6 cells).71 Currently, there is insufficient evidence to draw any 
conclusions on the benefits of meplazumab for the therapy of COVID-
19 patients. In an observational Chinese study, adults hospitalized 
with COVID-19 pneumonia (n = 17) who were treated with an intra-
venous infusion of meplazumab as an add-on therapy showed a higher 
recovery rate compared with controls (n = 11).197 However, these re-
sults should be interpreted with caution because they were gener-
ated in a nonrandomized, nonstratified study, with a small sample size. 
Large-scale studies are needed to assess the effectiveness and safety 
profile of meplazumab as a potential therapy for COVID-19.
8.7 | Is CP therapy a therapeutic option for severe 
COVID-19 infection?
CP therapy for COVID-19 treatment has yielded promising results. 
For example, in a trial of 10 severe COVID-19 patients,204 CP ther-
apy was well tolerated and improved the clinical outcomes. The viral 
load was undetectable after CP transfusion in 7 patients who had 
viremia. No severe adverse effects were observed. Other clinical 
trials have shown the beneficial effect of CP therapy in COVID-19 
patients, and ongoing clinical trials will provide additional data on 
its efficacy, safety and optimal timing for treatment (Table 2). In this 
regard, it is unclear whether in patients with a high viral load, such as 
severely ill patients, CP therapy may drive tissue pathology through 
immune complexes or complement activation.
8.8 | Do Janus kinase inhibitors represent 
a therapeutic option for severe COVID-19?
Baricitinib, fedratinib, and ruxolitinib are potent and selective 
JAK-STAT signaling inhibitors approved for indications such as 
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rheumatoid arthritis and myelofibrosis. These drugs are powerful 
anti-inflammatory medications that may reduce the systemic lev-
els of cytokines associated with COVID-19.205 Indeed, in a pilot 
study of 12 COVID-19 patients, baricitinib limited the CSS and 
was beneficial for the patients.206 The use of JAK inhibitors has 
been associated with a higher risk of opportunistic viral infections, 
such as herpes zoster, which suggests that the reduced inflamma-
tion caused by JAK inhibitors may limit, to some extent, antiviral 
responses.207
8.9 | What is the therapeutic value of ivermectin for 
treating SARS-CoV-2 infection?
Ivermectin (avermectin B1a and avermectin B1b) is an antiparasitic 
drug that has shown broad-spectrum antiviral activity in vitro. In 
SARS-CoV-2–infected fibroblasts (Vero-hSLAM cells), a single ad-
dition of Ivermectin at 2 hours postinfection reduced viral RNA 
~5000-fold at 48 hours.208 However, plasma concentrations of total 
and unbound ivermectin did not reach the IC50 determined in vitro, 
even at a 10 times higher dose than approved by the Food and Drug 
Administration (USA).209 Consequently, the likelihood of a success-
ful clinical trial using ivermectin is low.
8.10 | What is the evidence that 
hydroxychloroquine is effective for the treatment, or 
prophylaxis, of SARS-CoV-2 infection?
In an observational study of 1446 COVID-19 patients, 811 received 
hydroxychloroquine treatment, which did not change the risk of in-
tubation or death.210 Furthermore, in a Brazilian randomized con-
trol study evaluating 2 different doses of chloroquine in COVID-19 
patients with severe respiratory symptoms, mortality was 2.5 times 
higher in the high-dose chloroquine arm.211 Moreover, prepublished 
results from US Veterans Health Administration Hospitals did not 
support any advantages of hydroxychloroquine administered alone 
or with azithromycin.212 In addition, the results of a clinical study 
conducted in 821 individuals showed that hydroxychloroquine did 
not prevent illness compatible with COVID-19 or confirmed infection 
when used as postexposure prophylaxis within 4 days after expo-
sure.213 However, because of the retraction of two main papers on hy-
droxychloroquine treatment for COVID-19 patients, this area requires 
further attention by the European Medicines Agency and the Food 
and Drug Administration.
8.11 | What is the evidence for mesenchymal stem 
cell therapy in COVID-19 patients?
Mesenchymal stem cells may exert antiviral mechanisms in the con-
text of SARS-CoV-2 infection. The basal IFN-stimulated gene ex-
pression of mesenchymal stem cells is high, which enhances their 
responsiveness to IFN signaling, potentially inducing broad viral 
resistance. Mesenchymal stem cell therapy may potentiate the low 
IFN-I and IFN-III levels and moderate IFN-stimulated gene response 
reported in SARS-CoV-2–infected ferrets and COVID-19 patients.214 
It is being used in some centers, but its efficacy in COVID-19 has 
not been proven. Data available are mainly experimental with few 
records in humans and no reports on its efficacy in randomized clini-
cal trials.215
8.12 | Are common antihypertensive drugs useful 
in the prevention and treatment of COVID-19?
Common antihypertensive drugs inhibit ACE, but not ACE2. 
Importantly, ACE2 opposes ACE actions and lowers blood pressure 
by converting angiotensin-II (a vasoconstrictor peptide) into its me-
tabolites—angiotensin (1-7) (vasodilators).216 Other common related 
antihypertensive drugs are angiotensin-2 receptors blockers, which 
block AT-1, a receptor for angiotensin-II, through which it exerts its 
vasoconstrictor effect. However, AT-1 is not known to be used by 
SARS-CoV-2 to infect cells. It was shown in animal models that ACE 
inhibitors might increase ACE2 expression, thus increasing suscep-
tibility to infection. It has not been proven in humans, but it raised 
the concerns during the COVID-19 pandemic.216 Based on the data 
available to date, antihypertensive treatment with these medica-
tions should be continued.217
8.13 | What are the preclinical models available 
to investigate SARS-CoV-2 infection? Which ones 
resemble human COVID-19 the most?
At the moment, the animal model that resembles more closely 
human COVID-19 is the Rhesus macaque, whose ACE2 recep-
tor is identical to that in humans. This model recently showed that 
SARS-CoV-2 reinfection was hampered due to infection-acquired 
immunity and demonstrated the therapeutic effect of remdesivir in 
COVID-19 prior use in human clinical trials.218,219 The murine ACE2 
receptor is different from humans; hence, humanized murine models 
with recombinant human ACE2 are necessary.220
9  | SEC TION 8:  VACCINE DE VELOPMENT 
FOR COVID -19
9.1 | What are the most advanced vaccine 
candidates for COVID-19?
Previous vaccine research for SARS/MERS facilitates rapid trans-
lation.221 In the WHO vaccine platform, 110 candidate vaccines 
are in preclinical evaluation and 8 candidate vaccines are in clini-
cal evaluation for SARS-CoV-2 (adenovirus type 5 vector; LNP-
encapsulated mRNA; Inactivated; ChAdOx1; 3 LNP-mRNAs; DNA 
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plasmid vaccine with electroporation) as of May 15, 2020.222 The 
Coalition for Epidemic Preparedness Innovations provides dynamic 
status updates (https://cepi.net). Vaccine design may benefit from 
new knowledge of the structure and SARS-CoV-2–neutrailizing ca-
pacity of human antibodies.223 Recently, 206 monoclonal antibodies 
have been derived from SARS-CoV-2–specific B cells of 8 infected 
individuals, some of which showed potent SARS-CoV-2 neutraliza-
tion.224 In a similar fashion, another study has reported the isolation 
of 2 specific human monoclonal antibodies (CA1 and CB6) from a 
convalescent COVID-19 patient. CA1 and CB6 demonstrated potent 
SARS-CoV-2–specific neutralization activity in vitro. In addition, 
CB6, which recognizes an epitope that overlaps the receptor-binding 
domain, inhibited SARS-CoV-2 infection in rhesus monkeys at both 
prophylactic and treatment settings.225
9.2 | The thermal stability and chemical 
stability of single-domain antibodies position them 
as a potential therapy for viral infections. Could this 
approach be applied in COVID-19?
SARS-CoV, MERS-CoV, and SARS-CoV-2 are zoonotic pathogens. 
SARS-CoV spike protein-directed single-domain antibodies cross-
react with SARS-CoV-2 and MERS-CoV. In recent research, im-
munization of llamas with perfusion-stabilized spike proteins of 
betacoronavirus induced bivalent cross-reactive single-domain 
camelid antibodies that could neutralize SARS-CoV-2 pseudovi-
ruses. Crystallography has revealed that single-domain antibodies 
impede viral penetration into cells. The favorable biophysical and 
potent neutralization properties support the possibility of thera-
peutic use.226 Human monoclonal antibodies may offer similar neu-
tralization capacity with potential for better tolerability and a longer 
half-life.227
9.3 | Given that SARS-CoV-2 is predominantly 
a respiratory pathogen, could a nebulized vaccine 
be more effective in terms of bioavailability and 
function?
Single-domain antibodies have been investigated as potential ther-
apeutics for influenza, RSV, and HIV in addition to coronaviruses. 
SARS-CoV-2 mainly targets the respiratory tract; hence, the devel-
opment of vaccines directed to the respiratory epithelia and lung 
parenchyma using a nebulizer has been considered to maximize bioa-
vailability and function.228 Although active research against respira-
tory viruses has focused on aerosolized plasmid DNA vaccines, other 
forms of vaccine administration are currently further advanced in 
clinical trials.221 Veterinary medicine commonly uses aerosolized 
coronavirus vaccines for chicken farms.229
9.4 | When will a SARS-CoV-2 vaccine be available?
A novel vaccine platform requires careful evaluation and should 
ideally include toxicological studies in valid animal models. Early 
progress toward SARS vaccines has facilitated a “running start,” 
but standards of care and safety must be maintained. Acceleration 
rather than omission of clinical trials is key. Preliminary data from 
Oxford University is anticipated by mid-2020.221 Of note, a dose-
escalation, single-center, open-label, nonrandomized, phase 1 was 
conducted in 108 healthy individuals that received an Ad5-vectored 
COVID-19 vaccine. The vaccine was tolerable and immunogenic at 
28 days postvaccination. SARS-CoV-2–specific antibodies peaked at 
day 28 postvaccination, and specific T-cell responses were detected 
from day 14 postvaccination.230
10  | SEC TION 9:  EPIDEMIOLOGY OF 
COVID -19 AND ENVIRONMENTAL FAC TORS
10.1 | What are some characteristic aspects of the 
COVID-19 pandemic?
An important aspect is that COVID-19–associated mortality is very 
high, almost unavoidable when the pandemic control fails. This is 
due to rapid community spread, high community virus, especially 
in the elderly, and comorbid, but also in younger noncomorbid per-
sons, including healthcare workers, young adults, and children. The 
COVID-19 pandemic also seems to be characterized by a significant 
level of asymptomatic spread.231-233
10.2 | The iceberg of COVID-19: are there 
asymptomatic cases below the surface?
The number of COVID-19–diagnosed patients may represent just 
the tip of the iceberg. To date, epidemiological studies that pro-
vide an accurate idea of asymptomatic cases are scarce.4,5,107 Most 
of the identified asymptomatic cases are diagnosed by random 
screening of healthcare workers and individuals who had been 
in close contact with COVID-19 cases.59 In addition, there are a 
high number of asymptomatic individuals who have experienced 
COVID-19–like symptoms in their clinical histories without any di-
agnostic tests and hospital admission. Due to the nature of this 
disease, it is difficult to identify asymptomatic virus carriers, and 
it is one of the challenges faced in the containment of the pan-
demic.5 The real percentage of asymptomatic individuals and how 
long they carry the virus is unknown. Large screening studies for 
virus-specific IgM, IgG, and IgA will be a decisive factor in control-
ling the pandemic, as it is the main indicator of the development of 
population immunity.
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10.3 | What are the reasons for striking differences 
in the COVID-19 infection rate among countries 
with similar climate, lifestyle, and location at similar 
latitude?
The differences are almost entirely due to the timing and effective-
ness of public health interventions. Countries that failed to control 
did too little, too late, and allowed SARS-CoV-2 to rip through their 
population, with catastrophic outcomes. Those that intervened early 
effectively stopped the disease transmission.234
10.4 | What is the basic reproduction number 
(R0) of SARS-CoV-2?
It is difficult to determine as it varies greatly from country to coun-
try, depending on how well countries control their epidemics with 
widespread testing, case isolation, and vigorous contact tracing, 
testing, and isolation if positive. In countries that do this well, the 
R0 can be very low indeed. In countries that fail to control the 
spread of the virus, the R0 is high but unknown as SARS-CoV-2 
spreads untested and therefore undetected. It has been estimated 
to be ~2.2.235
10.5 | What differentiates the previous 
epidemiological distribution of SARS-CoV-1 and 
MERS-CoV to the current SARS-CoV-2?
SARS-CoV-2 transmits more readily than either SARS-CoV or MERS-
CoV. The R0 of SARS-CoV-2 is controversial, but if left unchecked, 
it is likely to be greater than 3-4. However, the R0 number cannot 
be precisely defined as no country has left it to spread completely 
unchecked. In any case, even when preventative measures are taken, 
the R0 of SARS-CoV-2 is higher than that of SARS-CoV (1.7-1.9) and 
MERS-CoV (<1).236 There is a considerable frequency of very mild 
COVID-19 patients and asymptomatic SARS-CoV-2–infected peo-
ple. This makes transmission control more challenging than either 
SARS-CoV or MERS-CoV, where illness is frequently more severe.
10.6 | What is the severity and risk level of children 
for SARS-CoV-2 infection?
Children are at low risk of severe COVID-19 outcomes.237,238 Most 
patients in pediatric age with SARS-CoV2 infection presented with 
no or mild clinical manifestations, including fever, fatigue, and dry 
cough. They were typically managed with supportive treatments 
only, and they had generally a favorable prognosis with a recovery 
within 2 weeks.239-241 Young children also frequently carry other 
respiratory viruses, which potentially limit SARS-CoV-2 infec-
tion, as reported for other viral infections.242 Differences between 
children and adults in the regulation of ACE2 expression may also 
play a role.45 ACE2 mRNA expression was high in type I and II al-
veolar epithelial cells, in nasal and oral mucosa and nasopharynx, in 
smooth muscle cells and endothelium of vessels from the stomach, 
small intestine, colon, and in the kidney of human adults (mean age 
52 ± 22).243 Interestingly, a recent study demonstrated age-depend-
ent ACE2 gene expression in the nasal epithelium, which was lowest 
in younger children and increased with age.244 In addition, CD147, 
CD26, and their molecular interaction proteins seem to be differ-
ently expressed in peripheral blood mononuclear cells and T cells in 
children in comparison with adults.10
10.7 | Are children involved in SARS-CoV-2 
transmission?
Many children remain asymptomatic, even when they have radio-
logic pneumonia detected on screening.238 Given that children are 
effective transmitters of other respiratory viruses,245 it is expected 
that they will be just as good at transmitting SARS-CoV-2.
10.8 | Which animals in nature have been so far 
shown to get infected with SARS-CoV-2?
Bats are likely the natural reservoir of SARS-CoV-2. In addition, 
related coronaviruses have been identified in Malayan pangolins, 
which are considered as an intermediate host between bats and 
humans. SARS-CoV-2 replicates poorly in dogs, pigs, chickens, and 
ducks, but ferrets, cats, and Rhesus macaques are permissive to 
infection.246
10.9 | What demographic factors are associated 
with severe COVID-19?
Data on the characteristics of severe COVID-19 patients are uni-
formly showing a correlation with age. According to the CDC 
National Vital Statistic System on COVID-19 fatal outcomes, death 
rate doubles with each decade after 45 years (National Vital Statistics 
System). Comorbidities have also been associated with more severe 
disease.14 In Italy247 and China,248 hypertension (OR 2.36), chronic 
respiratory disease (OR 2.46), cardiovascular disease (OR 3.42), and 
diabetes (OR 2.05) show a positive correlation with severity. Gender 
and ethnicity have also been shown to impact COVID-19 severity 
(see questions below).
10.10 | Does ethnicity influence the prevalence of 
SARS-CoV-2 infection?
Data on ethnicity and COVID-19 are scarce, and further research 
on ethnicity and COVID-19 outcomes is needed.249 However, 
the data available show a disproportionate number of COVID-19 
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deaths in Black, Asian, and minority ethnic backgrounds. In fact, 
one third of UK ICU admissions are reportedly from them.250 In 
the USA, African Americans had more COVID-19 diagnoses and 
deaths, after adjusting for age, poverty, comorbidities, and epi-
demic duration. These disparities are also seen in the Hispanic and 
Asian communities.251
10.11 | Are pregnant women at risk of COVID-19 
infection?
Pregnant women may be at a higher risk of poorer COVID-19 out-
comes because they have deficient IFN-α and IFN-λ responses to 
viral infections.252 However, reported pregnancy outcomes in 
COVID-19 are reassuring as they appear similar to nonpregnant 
adult women.253
10.12 | Are there specific treatments for pregnant 
women in case of severe COVID-19?
Testing treatments is problematic because pregnant women are ex-
cluded from most trials.254 It is known that azithromycin doubles in-
nate IFN production from virus-infected lung cells.255 It is safe for 
all trimesters of pregnancy256 and has been shown effective in high-
quality clinical trials of virus-induced lung disease.257,258
10.13 | Are men at a greater risk of SARS-CoV-2 
infection?
Given that the human ACE2 protein is encoded on the X chromo-
some, this may be relevant for male-female differences in outcomes, 
particularly in men with rare ACE2 coding variants as they will ex-
press those variants in all ACE2-expressing cells compared to a mo-
saic pattern of expression in women.259
Men may also have differences in certain innate antiviral re-
sponses compared with female counterparts.260 Outcomes in 
COVID-19 can be worse (~1.5-4 times worse) in terms of mortal-
ity, ICU admissions, hospitalizations,109,261,262 and case identifica-
tions263 for men than for women. Mortality in women can be lower 
by 30% up to age 60 in certain (but not all) countries. Outcomes 
after 60 years of age seem to continue unbalanced between the 
sexes.264,265
10.14 | How long will it take to generate robust and 
reliable data on COVID-19 prevalence?
There are reasonably robust data of COVID-19 deaths in hospitals 
because most people who die in hospital are tested. Deaths outside 
hospitals are likely underestimated as people are dying in care homes 
where mortality approaches ~40%,266 and may die without being 
tested and diagnosed. It is difficult to determine prevalence as test-
ing practices vary so much from country to country. Seroprevalence 
studies will help to collect these data.
10.15 | Is COVID-19 prevalence higher in 
industrialized countries?
COVID-19 was introduced rapidly to many industrialized countries 
as a result of air travel.267 Most of Europe and the USA probably 
did not react in a timely and efficient manner, resulting in the rapid 
spread and subsequent high mortality rates. In light of the dev-
astating situation in many European countries and the USA, less 
industrialized countries had a little more time to better prepare 
to control the pandemic.268 An important factor for prevalence 
studies is the percentage of the population that has undergone a 
diagnostic test, which seems to be at lower levels in developing 
countries.
10.16 | Will the summer weather decrease the 
SARS-CoV-2 spread?
Respiratory viruses spread less readily in summer than in winter for 
reasons that are not well understood. Dry air and higher tempera-
tures are slowing down the spread of respiratory viruses. Absence of 
school attendance, more time outdoors, greater household ventila-
tion, warmer temperatures facilitating virus inactivation, and higher 
vitamin D levels are all likely to play a part. Although social distanc-
ing measures are implemented, the summer weather should play a 
role in hampering the spread of COVID-19. However, based on the 
analogy of previous influenza pandemic, it is unlikely that summer, 
on its own, could stop transmission of SARS-CoV-2.269-271
10.17 | Is a second wave of COVID-19 expected to 
occur?
It largely depends on the SARS-CoV-2 seroprevalence developed in 
each country, which is still unknown. Countries that have had wide-
spread transmission may be hit by a second wave, but presumably 
with less severe consequences. Countries that effectively controlled 
the pandemic are at a higher risk of second wave of COVID-19 if 
those effective controls are relaxed due to the limited viral transmis-
sion and lack of active immunization.
10.18 | What is the evidence suggesting that SARS-
CoV-2 could become a seasonal infection rather than 
a transient pandemic?
SARS-CoV-2 has spread worldwide in humans, causing mild or no 
disease in many cases. It will continue circulating similar to other 
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human coronaviruses (229E, HKU1, NL63, OC43), and it may well 
become an endemic, seasonal virus.272
10.19 | What is the most efficient strategy to 
prevent SARS-CoV-2 infection?
The main route of SARS-CoV-2 transmission is via respiratory drop-
lets and aerosols.273-275 Avoidance of high virus loads, acquired 
through aerosol and droplet transmission, is paramount to prevent 
severe outcomes. Consequently, social distancing, masks, and hand 
sanitation are undoubtedly effective because they prevent the drop-
let and surface contact–associated initial high virus load and the in-
creased risk of severe disease.276-278
10.20 | What is the evidence supporting social 
distancing and face mask to prevent SARS-CoV-2 
infection?
A systematic review and meta-analysis has found that transmission 
of viruses was lower with physical distancing of 1 m or more, com-
pared with a distance of less than 1 (OR 0.18) and protection was in-
creased as distance was lengthened. In addition, face mask use could 
result in a large reduction in risk of infection (OR 0.15), with stronger 
associations with N95 or similar respirators compared with disposa-
ble surgical masks or similar. Eye protection also was associated with 
less infection (OR 0.22).279 Therefore, the COVID-19 pandemic can 
be controlled if social distancing is combined with widespread test-
ing, case isolation, vigorous contact tracing, and personal protection. 
Indeed, severe and critical illness among Chinese healthcare workers 
before January 10 was 45%, a time when personal protection equip-
ment and infectious control measures were likely not implemented. 
After February 1, when personal protection measures were in place, 
the percentage of severe and critically ill Chinese healthcare workers 
dropped to 8.7%.280
10.21 | What is the relative risk to contract SARS-
CoV-2 infection through surfaces?
SARS-CoV-2 remained viable in aerosols for 3 hours with a ~10-fold 
reduction in infectious titer.281 SARS-CoV-2 was more stable on 
plastic and stainless steel than on copper and cardboard; viable virus 
was detected up to 3 days after application to plastic and 2 days to 
stainless steel, on each surface, the virus titer was reduced nearly 
~100-fold.281 Importantly, sunlight exposure inactivated 98% of 
infectious SARS-CoV-2 every 6.8 minutes in simulated saliva and 
every 14.3 minutes in culture media. This study suggests that per-
sistence, and subsequently exposure risk, may vary significantly 
between indoor and outdoor environments.271 Therefore, it is con-
venient to minimize contact with surfaces touched by others (even 
before SARS-CoV-2 existed), particularly at indoor environments, 
for example, when using public transportation.
10.22 | What is the duration of viral shedding?
In 248 COVİD-19 patients, the estimated median time from symp-
tom onset to viral clearance in the nasal swabs was 11 days, while in 
asymptomatic cases, it was 2 days.282 In patients that recovered, the 
median duration of viral shedding was ~20 days, while in nonsurvivors, 
it was detected until death. The longest duration of viral shedding 
in survivors was 37 days.109 In addition, non-SARS-CoVs have been 
shown to be carried in the human respiratory tract without any cur-
rent infection283; this type of carrier may serve as a silent reservoir of 
SARS-CoV-2, thus contributing to its transmission. Cai et al analyzed 
the clinical characteristics of 298 patients with confirmed COVID-19 
and found that a slow viral clearance is associated with an increased 
risk of high disease severity with a 1% mortality rate.284
10.23 | Do some COVID-19 patients act as 
“superspreaders”?
The individual variation in the transmission of an infection is de-
scribed by a factor called “dispersion factor or k.” The lower the “k” 
value, the more transmission comes from a small proportion of in-
dividuals acting like superspreaders. Superspreading clusters have 
been observed in past coronavirus outbreaks (SARS/MERS), where 
a small number of infected individuals were responsible for a large 
proportion of secondary transmissions, with an estimated “k” of 
about 0.16 for SARS and 0.25 for MERS.285 It is unclear whether 
superspreading clusters have contributed to the COVID-19 out-
break. A simulation of early outbreak trajectories estimated that 
“k” for COVID-19 is higher than for SARS and MERS.285 However, 
in a recent preprint study, the estimate of “k” for SARS-CoV-2 was 
around 0.1, suggesting that around 10% of infected patients may 
have been responsible for 80% of secondary transmissions.286 
Individual variation in infectiousness is difficult to measure, as it 
is mostly empirical, but the identification of any SARS-CoV-2 su-
perspreading will be of primary importance for pandemic control.
10.24 | Are COVID-19-dedicated hospitals useful 
to limit SARS-CoV-2 infections and optimize the 
healthcare resources during the COVID-19 pandemic?
The designation of COVID-19–dedicated wards and personnel within 
hospitals is useful to limit nosocomial SARS-CoV-2 infections.123 It 
also allows other non-COVID-19 conditions to be treated using rou-
tine healthcare resources more safely and effectively. Maintaining 
such separation requires intensive SARS-CoV-2 testing in view of the 
high asymptomatic infection rate.287
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10.25 | Is a community-based strategy more 
effective, in comparison with a hospital-based one, to 
limit SARS-CoV-2 infections and optimize healthcare 
resources during the COVID-19 pandemic?
Community-based strategies are effective at controlling the trans-
mission of SARS-CoV-2. Australia, Hong Kong, Japan, Singapore, 
South Korea, and New Zealand have all controlled effectively. 
Their cumulative COVID-19 mortality is >100-fold less than that in 
Belgium, France, Italy, Spain, and the UK, countries that have had 
difficulties to adequately control the pandemic.146,288,289 It is impor-
tant to implement measures to contain the spread of the virus, such 
as developing models to predict SARS-CoV-2–related mortality.290
10.26 | May the elimination of the live animal 
market reduce the risk of future viral outbreaks?
Closing live animal markets is likely to reduce the risk of future viral 
outbreaks although this is not a practical way to prevent viral out-
breaks for multiple reasons including social and economic.
10.27 | Are new technologies (geolocation, phone 
apps, etc) useful to track people during quarantine?
This is an evolving area with a rapidly expanding interest. Many 
countries around the world are considering or are developing mobile 
phone apps capable of supporting rapid contact tracing and sup-
porting and monitoring social distancing.291 Their usefulness is yet 
to be proven, and there are privacy and ethical considerations that 
require open debate and careful planning.292
10.28 | What kind of lifestyle factors plays a role 
in the COVID-19 pandemic?
Lifestyle factors that may influence SARS-CoV-2 infection suscepti-
bility and COVID-19 severity include smoking, stress, diet, and alco-
hol intake, among others. For example, smoking has been shown to 
increase the susceptibility to respiratory tract infections and its se-
verity,293 and it is a risk factor for severe COVID-19.294 Moreover, al-
cohol consumption may impair antiviral immunity295; in vitro studies 
with human monocytes have shown that both acute and prolonged 
alcohol exposures inhibit type I IFN induction upon Toll-like receptor 
8 and 4 stimulation.296 Dietary habits may also play a role as obese 
patients have been shown to have a higher risk of developing severe 
COVID-19.297 Furthermore, there are bioactive food compounds 
with antiviral activity, such as resveratrol,298 although the amount 
of them obtained through the diet is unlikely to play a relevant role 
in COVID-19.
10.29 | Is there an association between the 
microbiota and COVID-19?
It is known that respiratory virus infection causes perturbations 
in the gut microbiota and that germ-free mice are more suscepti-
ble to viral infections, which intimates a role for the microbiota in 
COVID-19.299 However, the impact of the commensal microbiota on 
SARS-CoV-2 infection susceptibility and COVID-19 severity is un-
known.300 An essential step is identifying the bacterial species in-
teracting with SARS-CoV-2. This is rather challenging given the large 
number of bacterial species in the lung and respiratory tract,301 and 
especially in the gut. However, a number of lung metagenomic stud-
ies have reported an abundance of Prevotella in the lung of SARS-
CoV-2–infected patients.302 While in silico analysis have revealed 
that Prevotella proteins may promote viral infection,303 prospective 
studies are necessary to ascertain whether this is a consequence of 
the infection or a risk factor for it.
10.30 | Could the higher cleaning and disinfectant 
exposure during the pandemic increase the allergy 
prevalence in the general population?
It is well established that epithelial barrier defects and/or dam-
age favor the development of Th2 immunity.304,305 Increased hy-
giene, in general, and overexposure to epithelial barrier opening 
molecules, such as detergents, can promote the onset of allergic 
disease.306 To date, there is no evidence linking the COVID-19 
protective measures (gloves, hand sanitizers, etc) with increased 
allergy prevalence. In this regard, multifactorial epidemiological 
studies are needed. These studies should consider the impact on 
allergic diseases of virus-specific type 1 responses and psychoso-
cial and environmental changes caused by the pandemic and ef-
forts to contain it.
10.31 | The COVID-19 pandemic has reduced 
fossil fuels and environmental pollution. Could this 
change the exposome in the long term and alter the 
cause of allergic and other respiratory diseases?
Although there has been a significant change in pollution parame-
ters, unfortunately this reduction in pollution is transient and con-
sequently unlikely to be significant. The exposome-related allergy 
and asthma risk is multifactorial. It includes climate change, biodi-
versity, the microbiome, and nutrition among others, which have not 
changed during the pandemic.307 In addition, although pollution lev-
els have dropped, climate change still occurs at an accelerated pace. 
Lifestyle changes during the lockdown,308 weight gain, and increased 
exposure to indoor allergens and pollutants may even increase the 
incidence of allergic diseases in the long run.
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11  | CONCLUSION
With the rapid spread of COVID-19 at a pandemic scale, we are 
overwhelmed and drowned with a wealth of information. A global 
fight to contain the pandemic has started in which we need in-
ternational solidarity and prompt sharing of accurate scientific 
information. We strongly support the implementation of an open 
data concept for all COVID-19 studies, which should be performed 
with full transparency. A global strategy to reduce the burden of 
COVID-19 must be established. It is well known that these action 
plans can only be successful by combining efforts from stake-
holders: WHO, governments, researchers, physicians, patient 
organizations, economists, pharmacists, industry, and policymak-
ers. There is a pressing need to develop and implement global and 
regional COVID-19 guidelines on all aspect of this disease. The 
EAACI has immediately taken action on disseminating knowledge 
and developing official statements49,123,131,133 on how to handle 
allergy and asthma patients during the COVID-19 pandemic. As 
evidence on the epidemiology, course, and treatment of the dis-
ease is exponentially increasing, all the recommendations made 
by EAACI need to be regularly updated and amended in line with 
upcoming evidence.
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